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Platelet-activating factor acetylhydrolase (PAFAH) is elevated in atherosclerosis and may 
play a role in pathogenesis of this disease. Molecular mechanisms regulating the 
expression of this lipoprotein-associated PLA2 are indistinct. Mildy oxidized low density 
lipoprotein (oxLDL) and monocytes (the primary source of PAFAH) are co-localized in 
early atheromas. Monocytes are activated by oxidized phospholipids (oxPL) in the 
oxLDL particle. We hypothesized that oxPL-activated monocytes are the source of 
increased levels of PAFAH in atherosclerosis. We found that PAFAH expression is 
significantly induced by OxPAPC and in particular long-chain fractions of oxPAPC in 
monocytes and cytokine-differentiated DC, but not cytokine-differentiated MO. 
Furthermore, spontaneously differentiated MO and DC from monocytes of non-
periodontitis and aggressive periodontitis subjects, oxPAPC induced PAFAH in DC 
alone. 1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-phosphocholine (PEIPC) is a 
  xvii
particularly bioactive component of long-chain oxPAPC fractions that binds the 
prostaglandin receptor subtypes DP1 and EP2. We revealed using selective agonists and 
antagonists of these receptors that DP1 and EP2 are required for the induction of PAFAH 
expression. OxPAPC stimulates IL-6 release from monocytes and this cytokine is 
required for oxPAPC-induced PAFAH expression. We next tested the hypothesis that 
oxPAPC did not induce PAFAH in MO because a key component of the signaling 
machinery was lacking. Flow cytometric and immunoblot analyses demonstrated that 
MO express very low levels of IL-6 receptor in comparison to DC and monocytes. Based 
on these observations, we propose that long-chain oxPL induce PAFAH expression by 
binding DP1 and/or EP2 and stimulating IL-6 production. These data strongly support the 
hypothesis that oxLDL-activated DC are the source of high PAFAH levels in 
atherosclerosis. Platelet activating factor (PAF) is the inflammatory phospholipids for 
which PAFAH is named. PAF has been shown by other investigators to induce the 
expression of PAFAH. In our physiologically relevant monocytes, PAF suppresses 
PAFAH transcription and expression. 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-
phosphatidylcholine (POVPC) is a short-chain oxPL that signals through the PAF 
receptor. Our preliminary data suggest that like PAF, POVPC suppresses PAFAH 
expression in monocytes. Further investigation into the effects of the short-chain oxPL 
are warranted. Our data support the hypothesies that oxPL-activated DC are the source of 
high PAFAH levels in atherosclerosis.  
 
 
 1 
CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
 
1.1 Phospholipids 
Phospholipids are biological molecules composed of a hydrophobic tail group and a 
hydrophilic phosphate head group. They play an essential role as membrane lipids 
providing a barrier to the cell and also possess fatty acyl components that are important 
cellular energy stores. These crucial components of cellular membranes were originally 
identified as structural, somewhat inert molecules. However, phospholipids are now 
known to be biologically active molecules that mediate a wealth of signaling events both 
inside and outside the cell. 
 
Glycerophospholipids are composed of a diacylglycerol backbone, and a polar region 
comprising a phosphate group and an organic group such as choline. 
Glycerophospholipids are named according to the fatty acids esterified to their glycerol 
backbone as well as the nature of the organic head group. The glycerol backbone has 
three carbons denoted as sn-1, sn-2 and sn-3. Fatty acids are esterified to carbons at the 
sn-1 and sn-2 position while a phosphate and polar head group are present at sn-3. A 
glycerophospholipid with a choline head group, palmitic acid at sn-1 and arachidonic 
acid esterified at sn-2 is named 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine. 
Phosphatidylcholine (PC) is the most abundant of the phospholipids and is predominant 
in most mammalian membranes. The variation in fatty acids at sn-1 and sn-2 combined 
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with the diversity in head group moieties gives rise to hundreds of glycerophospholipids 
that possess differing structural and signaling properties.  
    3
 
 
 
 
 
 
Figure 1: Phospholipases A1, A2, C and D selectively Cleave Phospholipids. Each 
phospholipase (A1, A2, C or D) possesses the ability to cleave one of the susceptible 
bonds (shown in red). Taken from Molecular Cell Biology, Lodish et al., 5th Edition, 
2004 
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The enzymatic hydrolysis of PC at the sn-2 position results in the formation of lyso-
phosphatidylcholine (LPC) and free fatty acids. LPC is a detergent, and interferes with 
membrane integrity. It is present in minimal quantities in membranes. LPC is a pro-
inflammatory phospholipid in vitro and elevated levels are associated with diseases such 
as asthma and high levels are known to be present upon lipid particles in atherosclerosis 
(Mehta et al., 1990). The free fatty acids liberated in the enzymatic degradation of 
phospholipids by phospholipase A2 are signaling molecules and precursors to a variety of 
additional bioactive molecules. For example, arachidonic acid is a potent signaling 
molecule that exerts regulatory control over signaling enzymes such as several protein 
kinase C isoforms (McPhail et al., 1984). Arachidonic acid is also a key inflammatory 
intermediate in the production of the eicosanoids, which are important signaling 
mediators of inflammation and immunity. The eicosanoids are the prostaglandins, 
prostacyclins, leukotrienes and thromboxanes. Eicosanoids are produced by the 
conversion of arachidonic acid by selective enzymes (Figure 2). For example, the 
prostaglandins are produced by the action of the cyclooxygenase (COX) enzymes, either 
COX-1 (constitutively active) or COX-2 (inducible). Prostaglandin synthase enzymes 
may further modify the product of COX activity, prostaglandin H2 (PGH2). The outcome 
of this reaction is the production of a variety of PG species including PGE2 and PGD2 
(Figure 2). PGE2 and PGD2 elicit a variety of responses including vasodilation and are 
implicated in the pathogenesis of diseases such as asthma and cancer (Badawi and Badr, 
2003;Wenzel, 1997). The lipoxygenase pathway is mediated by 5-lipoxygenase that 
catalyzes the oxidation of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-
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HPETE). Further action of 5-lipoxygenase converts 5-HPETE to leukotriene A4 (LTA4). 
LTA4 is modified to yield further leukotrienes including LTC4, LTD4 and LTE4.  
    6
  
 
 
 
Figure 2: The Generation of Eicosanoids from Arachidonic Acid. Arachidonic acid is 
enzymatically modified by Lipoxygenase to HPETE and shuttled into the leukotriene 
synthesis pathway. Alternatively, arachidonic acid is converted to PGH2 by COX-1 or 
COX-2. PGH2 may be further modified by PGD synthase, PGE synthase and other PG 
synthases to produce an array of prostaglandins such as PGD2 and PGE2. Prostacyclins 
such as PGI2 are produced by the enzymatic coversion of PGH2 by prostacyclin synthase. 
Finally, thromboxane synthase converts PGH2 to thromboxanes such as TXA2 
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1.2 Platelet Activating Factor 
Platelet Activating Factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) is a 
specific phosphatidylcholine glycerophospholipid. Its activity was confirmed and name 
coined in 1974 by Benveniste (Benveniste, 1974). PAF was identified as a soluble factor 
released from IgE-stimulated basophils that activated platelets confirming earlier 
observations by other researchers (Henson, 1970;Siraganian and Osler, 1971). While the 
majority of glycerophospholipids possess an ester bond at the sn-1 position, PAF has an 
ether bond present in this position. The alcohol at the sn-1 position of PAF is usually 
hexadecanol although there are other species and these have been shown to have 
markedly different potencies. PAF is produced by a variety of cells including platelets, 
monocytes, macrophages and neutrophils (Benveniste, 1974;Elstad et al., 1989;Lynch et 
al., 1979). Multiple inflammatory stimuli induce the release of PAF including 
lipopolysaccharide (LPS), IgE, histamine and ATP (Benveniste, 1974;McIntyre et al., 
1985). PAF was also the first lipid demonstrated to bind a specific receptor to exert its 
biological effects. Prior to this, lipids were thought to exert their effects by interacting 
directly with the plasma membrane. However the discovery of the PAF receptor signaled 
the advent of the phospholipid-signaling field. It is now known that there are many 
phospholipids that bind receptors to elicit responses.  
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1.3 Phospholipases 
The phospholipases are an extensive family of enzymes that catabolyze 
glycerophospholipids. The thirty-five known enzymes may be classified according to the 
position at which they hydrolyze phospholipids, as demonstrated in Figure 1. 
Phospholipase A1 (PLA1) targets the sn-1 acyl chain and PLA2 targets the sn-2 acyl chain. 
PLC cleaves at the sn-3 position before the phosphate group releasing diacylglycerol and 
a phosphate-containing head group. PLD cleaves at the sn-3 position after the phosphate 
group releasing phosphatidic acid and an alcohol.  
 
The PLA2 family of enzymes itself is further subdivided into a variety of enzymes that 
share a common site of phospholipid hydrolysis but differ greatly in their mechanism of 
action, regulation and structures. The consequence of PLA2 activity is the hydrolysis of 
the sn-2 fatty acid from a phospholipid resulting in the production of lyso-phospholipid 
and the release of free fatty acid. The PLA2 enzymes are grouped based upon their 
functional similarities. They are divided into secreted, calcium dependent, calcium-
independent and the platelet activating factor acetylhydrolases (Table I). Within these 
groups there also exists a systemic numbering system (Schaloske and Dennis, 2006).  
    9
 
 
 
 
ENZYME MOLECULAR 
WEIGHT 
CALCIUM 
REQUIREMENT 
ACTIVE 
SITE 
EXPRESSION LOCATION REGULATION 
sPLA2 14-18 mM His-Asp Inducible Extracellular Expression 
cPLA2 
(α, β, γ) 
85 uM GLSGS Constitutive Cytosolic Ca2+, PO4 
(α,β) 
Ceramide-1-
Phosphate 
iPLA2 80 None GxSxG Constitutive Cytosolic Oligomerization 
PAFAH 
(secreted 
isoform) 
45 None GxSxG Inducible Extracellular Expression 
 
Table 1: Selected Mammalian Phospholipase A2 Subtypes 
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Members of the Secretory PLA2 (sPLA2) family are, as their name suggests 
extracellularly active. These small proteins range in size from 13-15kDa, possess an 
active site histidine and rely upon mM levels of calcium for their catalytic activity (Burke 
and Dennis, 2009). Enzymes of the sPLA2 family play key roles in mediating 
inflammation, immunity and atherosclerosis (Boyanovsky and Webb, 2009). Current 
research suggests that several of these enzymes, including group V and X, are pro-
atherogenic and an inhibitor that targets Group II, V and X (Varespladib) is currently in 
Phase II clinical trials for use in atherosclerosis (Fraser et al., 2009;Hanasaki et al., 
2002;Karabina et al., 2006). 
 
Calcium-dependent, cytosolic PLA2 (cPLA2) are larger proteins, between 61-114 kDa 
that possess an active site serine (Schaloske and Dennis, 2006). The cPLA2 group 
requires micromolar levels of calcium for its translocation to membranes (Schaloske and 
Dennis, 2006). cPLA2 selectively targets phospholipids with arachidonic acid at the sn-2 
position and is well-characterized as mediating inflammation upon its activation. The 
cPLA2 knockout mouse shows significant reproductive problems perhaps associated with 
the crucial role of cPLA2 in releasing arachidonic acid for the production of eicosanoids 
which are key to many reproductive processes (Bonventre et al., 1997). 
 
The calcium independent phospholipase A2 (iPLA2) group is comprised of cytosolic 
enzymes that do not require calcium for their activity. Parallel to the cPLA2 group, iPLA2 
relies upon an active site serine for catalytic activity. The best characterized of this group 
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is Group VIA iPLA2. First identified in 1985 by Ross et al, this enzyme is important for 
remodeling of membrane phospholipids during the cell cycle (Manguikian and Barbour, 
2004;Ross et al., 1985). Oligomerization is required for the activity of iPLA2 and it is 
known to have truncated proteins that lack the active site. These truncated proteins bind 
active iPLA2 rendering it catalytically inactive (Manguikian and Barbour, 2004). While 
ATP does not appear to be required for enzymatic activity, it does stabilize iPLA2 (Lio 
and Dennis, 1998).  
 
The final group of PLA2 is that of platelet activating factor acetylhydrolase (PAFAH). 
The members of this family are so-named because of their ability to hydrolyze the acetyl 
group at the sn-2 position of the inflammatory phospholipid platelet-activating factor 
(PAF). Two of the enzymes Group VIIB and Group VIII are intracellular enzymes while 
Group VIIA is secreted. Unlike other secreted members of the PLA2 family, PAFAH 
Group VIIA is calcium-independent (Schaloske and Dennis, 2006). From this point on 
the term PAFAH will refer solely to PAFAH Group VIIA.  
 
1.4 Platelet Activating Factor Acetylhydrolase 
PAFAH was first identified for its biological activity upon PAF. Its subsequent 
purification led to intense characterization of this unique enzyme (Stafforini et al., 
1987b). This calcium-independent enzyme hydrolyzes PAF producing lyso-PAF and 
acetate (Figure 4). Lyso-PAF was long considered to be an inert product however a 
recent study suggests that this product of PAFAH activity is biologically active. Lyso-
    12
PAF is revealed to play an opposing role to PAF in neutrophil and platelet activation 
(Welch et al., 2009). 
 
PAFAH hydrolyzes PAF and phospholipids with short sn-2 acyl chains. It is also able to 
target short-chain diacylglycerols, triacylglycerols and acetylated alkenanols (Min et al., 
2001). Gelb’s group first suggested that PAFAH is unusual in that it accesses its substrate 
from the aqueous phase (Min et al., 1999). Recent crystallization and modeling of 
PAFAH has confirmed that the active site of the enzyme is able to access substrates from 
the aqueous phase (Samanta and Bahnson, 2008). This is likely an important factor in the 
unique substrate specificity of PAFAH. While hydrolysis diminishes when acyl chain 
length is greater than 5-carbons, oxidation and fragmentation of the sn-2 residue greatly 
improves the susceptibility of the phospholipid to PAFAH. Short chain oxidized 
phospholipids such as 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycerol-3-phosphocholine are 
efficiently hydrolyzed and oxidation of residues up to 9-carbons long can be hydrolyzed 
at a rate similar to that of PAF itself (Stremler et al., 1989b;Stremler et al., 1991). The 
rate of hydrolysis of PAFAH does diminish with increasing sn-1 chain length, 
presumably correlated to a diminished degree of solubility (Min et al., 1999). PAFAH 
does not appear to have a preference for the nature of the sn-3 polar head group (Min et 
al., 1999). 
    13
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Mechanism of Action of PAFAH. PAFAH selectively hydrolyzes platelet 
activating factor or short-chain oxidized phospholipids, producing 
lysophosphatidylcholine and releasing free fatty acid.  
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PAFAH is a 45kDa enzyme that possesses a GXSXG motif typical of serine esterases and 
neutral lipases (Schaloske and Dennis, 2006). The serine residue located at the center of 
the motif is nucleophilic and is flanked by histidine and an acidic aspartate (Tjoelker et 
al., 1995). This catalytic triad of His351-Ser273-Asp296 is susceptible to agents that modify 
active site serines such as diisopropyl fluorophosphate (DFP), phenylmethylsulphonyl 
fluoride (PMSF) and Pefabloc-SC (Dentan et al., 1996;Stafforini et al., 1990). The 
catalytic activity of PAFAH is also susceptible to oxidative inactivation by free radicals 
and cigarette smoke extract (Ambrosio et al., 1994;Miyaura et al., 1992). 
 
PAFAH is primarily produced by monocytes and monocyte-derived cells however, it is 
also secreted by platelets, neutrophils, mast cells and in differentiating megakaryocytes 
(Foulks et al., 2009;Mitsios et al., 2006;Nakajima et al., 1997;Tjoelker and Stafforini, 
2000). PAFAH expression increases upon monocyte differentiation into macrophages and 
dendritic cells (DC). Macrophages possess high levels of PAFAH activity that are 
approximately 5-fold greater to those measured in DC (Al Darmaki et al., 2003;Stafforini 
et al., 1997c). Upon secretion into the plasma, PAFAH becomes associated with 
lipoprotein particles (Stafforini et al., 1987a). This circulating lipoprotein-bound form of 
the enzyme is identical to PAFAH but is often described as lipoprotein-associated 
phospholipase A2 (Lp-PLA2) to distinguish its location. Approximately 70% of plasma 
PAFAH activity is associated with LDL (Stafforini et al., 1987a). The association of 
PAFAH with lipoproteins occurs after their formation and occurs with ApoE-containing 
HDL- and ApoB100-containing LDL-particles (Stafforini et al., 1987a). PAFAH activity 
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does not associate with other lipoproteins such as chylomicrons and Very LDL (VLDL) 
suggesting that the conformation of these apolipoproteins or additional factors play a role 
in the binding of PAFAH (Stafforini et al., 1987a). PAFAH activity is stably associated 
with LDL and HDL at physiological pH. However, PAFAH activity associates with HDL 
in more acidic conditions.  Early studies on the purification of PAFAH revealed that a 
carboxyl terminal portion of ApoB co-purified with PAFAH implying that the proteins 
interact (Yamada et al., 1994). Further studies demonstrated that two domains within the 
PAFAH primary sequence are required for the binding of PAFAH to LDL. Residues 
tyrosine-205, tryptophan-115 and leucine-116 are required for the association of these 
proteins (Stafforini et al., 1999). Little is known regarding the association of PAFAH 
with HDL, however recent studies suggest that multiple residues in the carboxy terminal 
portion of PAFAH are required (Gardner et al., 2008). The majority of residues are not 
conserved between species. This is interesting given that PAFAH preferentially 
associates with HDL in most animal models including murine and bovine (Gardner et al., 
2008). PAFAH also associates with Lipoprotein (a) (Lp(a)), an atherogenic subclass of 
lipoprotein (Lawn et al., 1992). Lp(a) is composed of an LDL particle with the ApoB-100 
covalently linked by a disulfide bridge to apolipoprotein (a) (Lawn et al., 1992). PAFAH 
likely binds to apoB100 on these particles and interestingly, PAFAH activity associated 
with Lp(a) may be greater than that of LDL (Blencowe et al., 1995).  
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1.5 The Regulation of Platelet Activating Factor Acetylhydrolase 
The PAFAH gene is mapped to chromosome 6p12-21 and is composed of 12 exons 
(Stafforini et al., 1996). The PAFAH sequence is 1.5kb long and the protein encodes 441 
amino acids (Tjoelker et al., 1995). The N-terminus contains a 17 residue hydrophobic 
signal peptide that is predicted to target PAFAH for secretion (Tjoelker et al., 1995). 
Amino acids 18 to 41 encompass a propeptide sequence that is cleaved post-
translationally (Tjoelker et al., 1995). Constitutive PAFAH expression is dependent on 
Sp1 and Sp3 transcription factors and GC-boxes in the 5’ flanking regions (Wu et al., 
2003). PAFAH expression is modulated by a variety of inflammatory stimuli. For 
example, PAFAH is transcriptionally activated by lipopolysaccharide (LPS) a component 
of gram-negative bacteria (Wu et al., 2003). The activation of PAFAH by LPS is 
coordinated through the p38 MAPK pathway by Sp1 transactivation (Wu et al., 2004). 
Relative levels of Sp1 and Sp3 associated with the GC-box are similar in resting and 
LPS-stimulated cells. This suggests that the transcriptional activity of Sp1 and Sp3 in 
LPS-stimulated cells is induced through post-translational modification or associations 
with additional transcriptional regulators. The 5’ flanking region of PAFAH also contains 
11 putative signal transducer and activator of transcription (Stat) binding elements. Other 
inducers of PAFAH expression include Interferon gamma (IFNγ), Tumor necrosis factor 
alpha (TNFα) and PAF (Cao et al., 1998d). PAF stimulation of PAFAH transcription has 
been demonstrated in human embryonic kidney (HEK) cells stably expressing the PAF 
receptor (Cao et al., 1998d). However PAF suppresses PAFAH expression in human 
decidual macrophages (Narahara et al., 2003). Intriguingly, PAFAH expression is 
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increased dramatically upon differentiation of monocytes into macrophages through an as 
yet unknown mechanism (Elstad et al., 1989).  
 
1.6 PAFAH and Atherosclerosis 
PAFAH is closely connected to atherosclerosis (Packard et al., 2000b;Tselepis and 
Chapman, 2002a;Wilensky et al., 2008), however it is unknown whether it plays a 
protective or damaging role in the disease. This uncertainty stems from the knowledge 
that, although PAFAH degrades pro-inflammatory ox-PL, the products of this reaction, 
namely lysophosphatidylcholine (LPC) and free oxidized fatty acids may also be pro-
atherogenic (Ninio et al., 2004b). Lysophosphatidylcholine (LPC) is especially potent, 
inducing smooth muscle cell proliferation and migration leading to intimal vessel 
thickening, an event that is central to the pathology of atherosclerosis (Chai et al., 
1996;Kohno et al., 1998;Ross and Agius, 1992). LPC also induces adhesion and acts as a 
pro-chemoattractant to monocytes and T-cells (Kume et al., 1992;Radu et al., 2004;Rong 
et al., 2002).There are several examples of altered PAFAH activity and its consequences 
in vivo. For example a missense mutation in the PAFAH gene at nucleotide 994 results in 
transversion of Valine to Phenylalanine at amino acid 279 of the mature protein 
(Stafforini et al., 1996). This mutation results in the production of catalytically inactive 
PAFAH (Stafforini et al., 1996). This mutation is homozygous in approximately 4 
percent of the Japanese population (Stafforini et al., 1996) and has now also been 
identified in Kirghiz and Turkish populations (Balta et al., 2001). This mutation has been 
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correlated with increased incidence of stroke, myocardial infarction and atherosclerotic 
occlusive disease in the Japanese population (Hiramoto et al., 1997;Yamada et al., 
1998b;Yamada et al., 2000b). The V279F mutation is also associated with increased 
intimal media thickness in type 2 diabetes patients (Yamamoto et al., 2003). In animal 
models, PAFAH gene transfer by adenovirus reduces atherosclerosis in Apo E-/- mice 
(Quarck et al., 2001a) and PAF-antagonists reduce lesion size (Subbanagounder et al., 
1999). PAFAH forced expression reduces neointimal formation and atherosclerosis in 
animal models  (Arakawa et al., 2005b;Quarck et al., 2001d;Turunen et al., 2005b). 
PAFAH also restores trafficking of DC to the secondary lymphoid tissues of apoE-/- mice 
limiting promotion of the chronic inflammatory responses associated with progression of 
atherosclerosis (Angeli et al., 2004b). PAFAH protection in these instances is likely 
connected to the catabolism of pro-atherogenic ox-LDLs and/or protection of lipoproteins 
from oxidation (Noto et al., 2003b;Stafforini et al., 1997e;Stremler et al., 1989b;Watson 
et al., 1995). 
 
Conversely, elevated PAFAH appears to be associated with increased incidence of 
coronary artery disease in European populations (Blankenberg et al., 2003a;Stafforini et 
al., 1987a;Stafforini et al., 1997d). There are associations between elevated plasma 
PAFAH and a variety of cardiovascular diseases such as coronary artery calcification, 
myocardial infarction and ischemic stroke (Ballantyne et al., 2004a;Ballantyne et al., 
2005b;Blake et al., 2001b;Johnston et al., 2006b;Koenig et al., 2004;O'Donoghue et al., 
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2006;Packard et al., 2000b). PAFAH is detected at significantly elevated levels in the 
lesions of Watanabe hyperlipidemic rabbits compared to normal aortas of control animals 
(Hakkinen et al., 1999). PAFAH is also detected at elevated levels in human 
atherosclerotic lesions and is directly associated with lesion severity (Hakkinen et al., 
1999). An inactivating mutation (Ala379Val) located near the Histidine of the PAFAH 
catalytic triad (His351) has been linked to decreased risk of myocardial infarction 
(Abuzeid et al., 2003;Ninio et al., 2004a). Products of the PAFAH reaction have been 
demonstrated to be proinflammatory and may exacerbate atherogenesis (Chen, 
2004a;Tselepis and Chapman, 2002a). The PAFAH inhibitor, Darapladib is currently in 
Phase III clinical trials. Thus far, Darapladib has been shown to transiently decrease 
circulating C-reactive protein (CRP) and interleukin-6 (IL-6) (Mohler, III et al., 2008). 
Importantly, these studies reveal that inhibition of PAFAH leads to a reduction in 
necrotic core progression suggesting that PAFAH may play a role in early atherosclerosis 
development (Wilensky et al., 2008).  
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1.7 Liproproteins 
Lipoproteins are a group of macromolecules present in plasma. They are composed of a 
neutral core of lipids triacylglycerol and cholesteryl esters, enclosed by a monolayer of 
phospholipids and free cholesterol. Cholesterol transport is facilitated by lipoprotein 
particles that carry cholesterol in either esterified or free form, to and from the liver. The 
particle is associated with one or more apolipoproteins depending upon the lipoprotein 
subtype (Table II). There are five types of lipoproteins; chylomicrons (CM), very low 
density lipoprotein (VLDL), Low Density Lipoprotein (LDL), Intermediate Density 
Lipoprotein (IDL) and High Density Lipoprotein (HDL). Perhaps the best characterized 
of the lipoproteins is low-density lipoprotein (LDL), the primary carrier of cholesterol to 
cells, and high density lipoprotein (HDL) that transports cholesterol from cells to the 
liver. Lipoproteins synthesis may be grouped into the exogenous or endogenous 
pathways. The exogenous pathway transports dietary lipids while the endogenous 
pathway transports lipids of hepatic derivation.  
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Lipoprotein Density 
g/ml 
Diameter
nm 
Apolipoproteins 
Chylomicron (CM) <0.94 75-1200 A-I, A-II, AIV,  
B-48,  C-I, C-II,  
C-III, E 
Very Low Density Lipoprotein 
(VLDL) 
0.94-1.006 30-80 B-100, C-I, C-II, C-
III, E 
Low Density Lipoprotein (LDL) 1.006-
1.063 
18-25 B-100 
High Density Lipoprotein (HDL) 1.063-1.21 5-12 A-I, A-II, C-I, C-II,  
C-III, E 
 
Table 2: Properties of the Lipoprotein Species 
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Ingested triglycerides and cholesterol are absorbed through the intestine and packaged 
into CM in the endoplasmic reticulum of intestinal enterocytes (Brown et al., 1981). 
During the packaging process, CM become associated with apoB-48, a truncated version 
of the apoB100 protein. ApoB48 is required for CM assembly and is crucial for structural 
integrity of these lipoprotein particles. Individuals that lack apoB48 (Anderson’s disease) 
do not have the ability to secrete CM from the intestine and have hypocholesterolemia 
(Dannoura et al., 1999). CM synthesis also requires the transfer of triglycerides into the 
nascent apoB particle, an event that is dependent upon the activity of microsomal transfer 
protein (MTP) (Berriot-Varoqueaux et al., 2000). Once CM become associated with 
lipoproteins apoAI and apoCII they are released from the cell by exocytosis, secreted into 
the lymph and then enter the bloodstream (Brown et al., 1981). ApoC and apoE are then 
transferred from HDL to CM particles. CM-associated apoCII activates the enzyme 
lipoprotein lipase (LpL) on the luminal face of the endothelial cell surface. LpL liberates 
free fatty acids from the CM particle that are absorbed by cells for energy. Excess surface 
material (phospholipids and free cholesterol) of the depleted CM are transferred to HDL 
(HAVEL, 1957). The remainder of the chylomicron remnant binds its receptor on the 
liver and is internalized and degraded by lysosomes.  
 
In the endogenous pathway, nascent VLDL is produced by the liver and, like CM 
production, requires MTP. VLDL is associated with apoAI and apoB100 upon its release, 
although there are no exposed binding sites for apoB100 at this stage. Nascent VLDL 
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becomes a mature particle following its association with ApoC and apoE, and the 
addition of phospholipids, all donated by HDL. ApoC association results in the activation 
of LpL, which converts VLDL to IDL by hydrolyzing triacylglycerol and releasing, free 
fatty acids. VLDL surface remnants are shuttled to the HDL pool while the remaining 
IDL is further modified. Cholesterol ester transfer protein (CETP) facilitates the removal 
of cholesterol esters from HDL to IDL and triacylglycerol and phospholipids from IDL to 
HDL. This process results in the formation of LDL particles. This LDL particle contains 
approximately 1500 molecules of cholesteryl ester, 800 molecules of phospholipid, 500 
molecules of free cholesterol and a single molecule of apolipoprotein B100 (apoB100) 
(Deckelbaum et al., 1977) (Figure 4). ApoB100 is a large, complex protein that is 
composed to 4,536 amino acids and has a molecular mass of 550kDa (Ginsberg and 
Fisher, 2009). ApoB-100 is required for structural integrity as well as receptor 
recognition of LDL. Cholesterol is an essential component of cellular membranes and is a 
precursor of bile acids and steroid hormones. For cells to take up cholesterol, LDL must 
bind its receptor upon cell membranes. The LDL receptor (LDL-R) is a transmembrane 
glycoprotein that binds apoB upon LDL. LDL-R sits in clathrin coated pits upon the cell 
surface. When LDL binds its receptor, a vesicle is pinched off and is endocytosed to the 
internal cell. The low pH of the lysosomal compartment results in the dissociation of 
receptor and LDL. The receptor is recycled to the cell surface while the LDL is broken 
down into amino acids and cholesterol. Excess cholesterol by the endocytosis of LDL or 
by surplus synthesis by the cell leads to the down-regulation of LDL-R synthesis in a 
tightly regulated fashion (Brown et al., 1981). 
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Mutations exist in ApoB that have physiologically detectable outcomes for example in 
patients with Familial defective Apolipoprotein B-100 (FDB). The critical region in 
ApoB for binding to the LDL receptor is located between residues 3359-3369 and is often 
referred to as “site B” (Boren et al., 2001). FDB patients possess a substitution mutation 
at position 3500 that leads to the substitution of a glutamine for an arginine at residue 
3500 (Boren et al., 1998). This mutation results in a conformational change in the C-
terminus of ApoB that prevents correct exposure of the critical region. Ultimately this 
decreases the affinity of LDL for its receptor by 95% or more. The outcome of this 
mutation is severely decreased LDL uptake and therefore hypercholesterolemia (Boren et 
al., 1998).   
 
LDL species are subclassified into four different groups based upon their size, density, 
charge, lipid content and apolipoprotein content (Berneis and Krauss, 2002). These 
groups are denoted as LDL-I, -II, -III and –IV and range from large, buoyant LDL to 
small, dense LDL (Krauss and Burke, 1982). Individuals with a prevalence of large, 
buoyant, cholesterol-rich LDL are described as possessing a Pattern A profile while those 
with mainly small dense LDL (usually LDL-III) are grouped as Pattern B. Some of the 
characteristics that the Pattern B profile is associated with include increased plasma 
triglycerides, elevated plasma apoB and reduced HDL-cholesterol (Austin et al., 1988). 
Small dense LDL are rich in triglycerides, are more likely to be taken up by arterial tissue 
than larger LDL and have decreased receptor uptake and increased proteoglycan binding 
(Bjornheden et al., 1996;Camejo et al., 1985;La Belle and Krauss, 1990). These results 
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reveal that small dense LDL are more proatherogenic than large, buoyant LDL. This is in 
agreement with further observations that show small dense LDL to be more susceptible to 
oxidation. PAFAH activity preferentially associates with small dense LDL (Karabina et 
al., 1994;Tselepis et al., 1995). 
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Figure 4: LDL Particle Composition The LDL core is primarily composed of free 
cholesterol and triacylglycerol. The outer particle surface of phospholipids, cholesteryl 
esters and a single protein molecule of apolipoprotein B-100 surround this. Taken from: 
Lehninger Principles of Biochemistry, 3rd Edition, 2000 
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1.8 High Density Lipoprotein 
HDL is well characterized as the lipoprotein that carries cholesterol from peripheral 
tissues to the liver (Lewis and Rader, 2005). While elevated plasma levels of LDL are 
associated with an increased risk of atherosclerosis, elevated HDL is considered to be 
protective. HDL is formed by the release of lipid poor apoAI from the liver and intestine 
(Lewis and Rader, 2005). Cholesterol, phospholipids and apolipoproteins are transferred 
to the nascent HDL by the action of LpL upon CM. Finally, the enzyme lecithin 
cholesterol acyl transferase (LCAT) esterifies HDL free cholesterol leading to the 
formation of mature HDL with a cholesterol ester enriched core. HDL directly removes 
excess cholesterol and phospholipids from the liver and peripheral tissues by receptors 
such as scavenger receptor BI (SR-BI) and ATP-binding cassette transporter A1 
transporter (ABCA1). This process allows further maturation of the HDL particle. 
Cholesterol ester hydrolase (CEH) is the rate-limiting enzyme that is chiefly responsible 
for the removal of excess cholesterol from peripheral tissues (Ghosh and Grogan, 1989). 
CEH releases free cholesterol that is then transferred to HDL where it is re-esterified by 
LCAT (Rothblat et al., 2002). Cholesterol may also be transferred from HDL in an 
indirect fashion by exchange with VLDL. This process is mediated by the enzyme 
cholesterol esterase transfer protein (CETP) (Lewis and Rader, 2005). Cholesterol is 
exchanged with triglycerides and consequently VLDL are processed to LDL particles 
which are removed from the circulation upon binding the LDL-R (Lewis and Rader, 
2005).  
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1.9 Atherosclerosis 
Cardiovascular diseases are the number one cause of death in the United States according 
to statistics by the American Heart Association. In the year 2006 statistical data revealed 
that eighty million Americans suffer from one or more forms of cardiovascular disease. 
The World Health Organization Report on the global burden of death revealed that 
cardiovascular diseases are the leading cause of death worldwide. This group of diseases 
accounts for thirty two percent of female deaths and twenty seven percent of male deaths 
(World Health Organization, Global Burden of Disease Report, 2004) Globally, 
cardiovascular diseases are the number one cause of death and is projected to remain so. 
An estimated 17.5 million people died from cardiovascular disease in 2005, representing 
30 % of all global deaths. Of these deaths, 7.6 million were due to heart attacks and 5.7 
million due to stroke. About 80% of these deaths occurred in low- and middle-income 
countries. If current trends are allowed to continue, by 2015 an estimated 20 million 
people will die from cardiovascular disease (mainly from heart attacks and strokes) 
(World Health Organization, Global Burden of Disease Report, 2004). Cardiovascular 
diseases include but are not restricted to aneurysm, atherosclerosis, stroke, coronary 
artery disease and myocardial infarction.  
 
The word atherosclerosis comes from the Greek: athero (meaning paste) and sclerosis 
(hardness). Atherosclerosis involves the deposition of lipid, cells and other substances in 
the walls of the artery; the arterial intima. Over time these deposits harden, becoming a 
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plaque. While the accumulation of lipids signals the onset of atherosclerosis, the ensuing 
inflammation is responsible for the outcome of the disease (Ross, 1999). There are six 
clinical stages of atherosclerosis development that define the changes occurring in the 
vessel wall from the development of the fatty streak to the development of the thrombus. 
Atherosclerosis is the underlying cause of cardiovascular disease. The narrowing and 
hardening of the artery walls during the process of atherosclerosis may result in blood 
clots blocking arteries leading to heart attack or stroke.  
 
As illustrated in Figure 5, atherosclerosis begins with the migration of LDL from the 
bloodstream into the artery wall. This event occurs early in life with fatty streaks, the first 
sign of lipid deposition, measured in juveniles (Katsuda et al., 1992)(Table 3) although 
this by itself is not sufficient to cause adverse outcome as atherosclerosis complications 
are generally not observed until subjects reach middle age. Progressive build up of LDL 
results in the narrowing of the vessel wall and late onset atherosclerosis is associated with 
a hardening of this deposit, which is called the plaque. Upon its transcytosis to the arterial 
intima, positively charged LDL interacts with negatively charged proteoglycans of the 
extracellular matrix (Camejo et al., 1985). This traps LDL in the intima and renders it 
susceptible to oxidative modification. LDL modification is not attributable to any 
individual agent. Proposed mediators of LDL oxidation include sPLA2, reactive oxygen 
species (ROS) and exposure to cell-derived oxidants in the sub-endothelial space as LDL 
traverses from the bloodstream to the intima (Bey and Cathcart, 2000;Hanasaki et al., 
    30
2002;Huber et al., 2002). These initial steps in oxidation may initiate a series of chain-
events that further modify LDL. The oxidative modification of LDL leads to an LDL 
particle that is no longer recognized by the LDL receptor. Instead, a class of receptor 
called scavenger receptors that include CD36 and SR-BI is responsible for binding and 
internalizing modified LDL (Goldstein et al., 1979;Henriksen et al., 1981). Patients with 
non-functional LDL receptors such as those with FDB or Familial hypercholesterolemia 
(FH) have a prolonged circulation of LDL. This results in a greater likelihood of LDL 
transcytosing to the arterial intima, therefore an increased opportunity for LDL 
modification thereby signaling the accelerated development of atherosclerosis.  
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Figure 5: Summary of Events Occuring in the Arterial Intima During 
Atherosclerosis. 1. Monocytes adhere to adhesion molecules on the endothelial cell 
surface on the luminal face of the artery wall before chemotaxing to the arterial intima. 2. 
Monocytes then differentiate into macrophages (or Dendritic cells). 3. LDL transcytoses 
from the arterial intima and is rapidly oxidized to oxLDL. 4. oxLDL is recognized by 
scavenger receptors (SR) upon the macrophage cell surface and phagocytosed. This 
continued process leads to the formation of foam cells that contain cytoplasmic 
cholesterol droplets. 5. The efflux of cholesterol is coordinated as reverse cholesterol 
transport by HDL. (Taken from Molecular Cell Biology 5th Edition. Lodish et al., 2004).  
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Stage Description 
Type I: Initial Isolated foam cells, onset, first decade 
Type II: Fatty Streak Intracellular Lipid Accumulation, first decade 
Type III: Intermediate Small intracellular lipid pools and intracellular lipid 
accumulation, third decade 
Type IV: Atheroma Core of extracellular lipid and intracellular lipid accumulation, 
third decade 
Type V: Fibroatheroma Lipid core and fibrotic layer, fourth decade 
Type VI: Complicated Surface Defect Thrombus, fourth decade 
 
Table 3: Stages in Atherosclerosis Development   
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1.10 Immune cells and Atherosclerosis 
Both lipid and protein components of the lipoprotein particle are modified. The most 
important of these modifications, with respect to atherosclerosis, is the oxidation of 
phospholipids, which produces an array of potent inflammatory mediators (Tsoukatos et 
al., 1997). OxLDL and its constituents signal the upregulation of adhesion molecules 
such as intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) upon the surface of endothelial cells lining the artery wall 
(Cominacini et al., 1997). This facilitates the binding of monocytes which are then 
induced to chemotax to the arterial intima where oxLDL signals monocyte differentiation 
to macrophages (Frostegard et al., 1990). Macrophages express a variety of scavenger 
receptors upon their cell surface that facilitate the uptake of oxLDL. While the LDL-R is 
tightly regulated, scavenger receptors are not controlled in a similar fashion. This allows 
the continued uptake of oxLDL by macrophages till they are heavily lipid-laden. The 
excess lipid droplets within the cell give them a histologically foamy appearance, which 
has led to the term “foam cells”. CD36 and SR-BI are classic examples of scavenger 
receptors that are known to recognize oxLDL and promote atherosclerosis through 
macrophage foam cell formation (de Villiers and Smart, 1999;Nakagawa-Toyama et al., 
2001). However, ApoE null mice lacking CD36 and SR-BI exhibited increased 
atherosclerosis compared to ApoE null control mice suggesting that there are additional 
receptors key to the advancement of atherosclerosis (Moore et al., 2005). OxLDL, but not 
native LDL is recognized by antibodies such as anti-Phosphorylcholine IgG (anti-PC) 
and anti-cardiolipin (anti-CL) (Schenkein et al., 2001;Tuominen et al., 2006). These 
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antibodies bind epitopes of oxLDL and lead to the opsonization of oxLDL through the Fc 
receptor. The enhanced uptake of oxLDL by macrophages and DC would potentially lead 
to increased foam cell formation. While macrophages are classically associated with 
atherosclerosis, accumulating evidence indicates an important role for dendritic cells 
(DC) the other monocyte-derived cell (Parums, 1992;Tabas, 2000). DC are potent antigen 
presenting cells that are uniquely adapted to activate naive T-cells (Johnston et al., 
2006b). DC are present in atherosclerotic lesions and are also rich sources of 
inflammatory cytokines that promote chronic inflammation in atherosclerosis (Bobryshev 
et al., 2001;Bobryshev, 2005;de Kleijn and Pasterkamp, 2003;Lord and Bobryshev, 
1999;Ozmen et al., 2002). oxLDL promotes DC maturation and exacerbates 
atherosclerosis (Alderman et al., 2002;Coutant et al., 2004;Perrin-Cocon et al., 2001). 
Additionally, DC are highly phagocytic and have been demonstrated to take up oxLDL 
and become foam cells (Bobryshev, 2006).  
Other immune cells that have been linked to atherosclerosis include mast cells, T-
lymphocytes and B-lymphocytes. Mast cells are bone-marrow derived cells that reside in 
tissues. Mast cells are found in arteries throughout atherosclerosis development, 
especially in rupture-prone shoulder regions (Jeziorska et al., 1997;Kaartinen et al., 
1994). Activated mast cells release a host of inflammatory mediators including proteases 
and cytokines. The mast-cell derived proteases chymase and tryptase can influence the 
atheroma by degrading components of the extracellular matrix (Johnson et al., 1998) as 
well as apolipoprotein B100 (Kokkonen et al., 1986). Additionally, activated mast cells 
release the cytokines IL-8 and MCP-1. Both are chemokines that promote the recruitment 
    35
of monocytes to the atheroma highlighting the potential for mast cells in atherosclerosis 
development (Gerszten et al., 1999). Furthermore, mast cells express the chemokine 
receptors CXCR2 (IL-8) and CCR5 (RANTES, MIP1α and MIP1β) (Gurish and Austen, 
2001). These cytokines are all produced in atherosclerosis by other immune cells and are 
potentially important for the homing of mast cells to the atheroma.  
 
T-lymphocytes are cells of the adaptive immune response. T-lymphocytes (T-cells) 
possess the T-cell receptor (TCR) that binds antigens. Activated T-cells are present in 
human atherosclerotic plaques at sites of fibrous cap (Jonasson et al., 1986). ApoE null 
mice crossed with the immunodeficient SCID model mouse have significantly reduced 
atherosclerosis compared to ApoE null mice (Zhou et al., 2000). The adoptive transfer of 
CD4+ T cells to ApoE null mice leads to elevated atherosclerosis (Zhou et al., 2000). B-
lymphocytes (B-cells) develop in the bone marrow and are antibody-producing cells. 
Antibodies that recognize oxLDL are found in humans and mice (Palinski and Witztum, 
2000;Wu and Lefvert, 1995). Knockout of B-cells leads to increased atherosclerosis in 
LDL-R null mice (Major et al., 2002). ApoE null mice with substantial atherosclerotic 
lesions have significantly increased costimulatory molecule expression compared to age-
matched controls (Afek et al., 2004). Activated B-cells express CD-80, a molecule that is 
required for co-stimulation of T-cells. Circulating B-cells expressing CD-80 are observed 
in atherosclerosis and correlate with disease severity (Tanigawa et al., 2003). Altogether 
these data suggest roles for both B-cells and T-cells in atherosclerosis development. 
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1.11 Animal Models of Atherosclerosis 
Apolipoprotein E null mice are the classic atherosclerosis animal model. Mice do not 
normally develop atherosclerosis; however the targeted deletion of apoE, a rare mutation 
in the human population, leads to the retention of lipoproteins in the circulation. 
Homozygous deletion of apoE in mice results in elevated LDL and VLDL (Roselaar et 
al., 1996). Mice develop severe hypercholesterolemia and atherosclerosis and this process 
is greatly accelerated by the switching from a regular chow diet to a lipid-rich, Western 
diet (Nakashima et al., 1994). ApoE is required for receptor binding and is present 
predominantly in HDL. HDL is the primary circulating lipoprotein in mice. This mouse 
model is not ideal. There are stark differences in cholesterol metabolism as well as in the 
lipid profile of the animals versus humans. ApoE null mice have high plasma cholesterol 
however the majority of this is confined to VLDL instead of LDL, as it is in humans 
(Roselaar et al., 1996). ApoE null mice contain oxidation-specific epitopes in both 
plasma and in atherosclerotic lesions in macrophage-rich regions and later, in necrotic 
regions that are recognized by anti-PC and anti-CL antibodies (Palinski and Witztum, 
2000).  
 
Human subjects with defects in LDL uptake such as patients with familial defective 
apolipoprotein B-100 (FDB) have hypercholesterolemia that renders them susceptible to 
premature atherosclerosis (Alonso et al., 2008;Boren et al., 2001). LDL-R knockout mice 
were designed as an animal model of hypercholesterolemia (Ishibashi et al., 1993).  
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LDL-R knockout mice maintained on a chow diet have elevated plasma cholesterol and 
slowly develop atherosclerosis though the implementation of a lipid-rich diet that 
accelerates the disease. At one month, the lesion morphology of LDL-R null mice is 
similar to that of the apoE null mouse (Roselaar et al., 1996). The LDL-R model has 
more modest lipoprotein abnormalities than the apoE model and do not develop 
atherosclerosis on a regular chow diet (Ishibashi et al., 1993). The ApoE and LDL-R 
knockout mice were crossed to breed a double knockout animal (Ishibashi et al., 1994). 
The first study did not report that these animals had a greater propensity to develop 
atherosclerosis than apoE null mice. However, a more recent study reported that the 
animals displayed a modestly increased propensity of atherosclerosis development 
(Witting et al., 1999).  
 
1.12 Oxidized Phospholipids 
LDL oxidation leads to the production of many lipid species. 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) is an abundant phospholipid 
present upon the LDL particle (Podrez et al., 2002b). While PAPC is just one example of 
an LDL-associated phospholipid that is susceptible to oxidation, its relative abundance 
has led to its use as a “model” lipid in the field of oxPL-signaling. Oxidized PAPC 
(oxPAPC) is measured in minimally modified LDL as well as in atherosclerotic lesions 
and in additional sites of chronic inflammation (Watson et al., 1997c). oxPAPC is 
produced from PAPC in vitro for signaling studies. This method involves the air 
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oxidation of PAPC for 24-48 hours (Watson et al., 1997c). OxPAPC comprises numerous 
bioactive lipid mediators notably the short-chain lipids 1-palmitoyl-2-(5-oxovaleroyl)-sn-
glycero-3-phosphatidylcholine (POVPC) and 1-palmitoyl-2-glutaroyl-sn-glycero-3-
phosphatidylcholine (PGPC) as well as long chain lipids such as epoxy-isoprostane- 
phosphatidylcholine (PEIPC) (Leitinger, 2003) (Figure 6). OxPAPC and its constituents 
have been shown to mediate many pro-atherogenic events including adhesion, 
chemotaxis and differentiation of monocytes (Frostegard et al., 1997b). For example, 
oxPAPC induces the chemokines monocyte-chemoattractant protein-1 (MCP1) and 
interleukin-8 (IL-8) in endothelial cells (Lee et al., 2000;Yeh et al., 2001). Topical 
application of oxPAPC to murine carotid arteries leads to a robust induction of the 
inflammatory cytokine interleukin 6 (IL-6) (Furnkranz et al., 2005c). oxPAPC-induced 
expression patterns in IL-6 null mice are mimicked by IL6 (Van Lenten et al., 2001c). 
These data indicate oxPL as critical regulators of genes associated with atherosclerosis. 
Oxidized phospholipids may be grouped according to the length of their sn-2 acyl chain 
into short- or long-chain lipids. Figure 7 illustrates a representative mass spectra for 
oxPAPC where each peak indicates an individual oxPL species. Short-chain oxidized 
phospholipids such as PGPC and POVPC are more likely targets for PAFAH given their 
short sn-2 acyl chain (Stremler et al., 1991). However, recent data have revealed that 
long-chain oxidized phospholipids like PEIPC are also hydrolyzed by PAFAH though 
less efficiently (Davis et al., 2008). Recent efforts have focused upon determination of 
the specific effects of oxPAPC components and the receptors they signal through. This 
has, in part been fueled by the findings that the mice lacking CD36 and SR-BI exhibited 
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increased atherosclerosis (Moore et al., 2005). CD36 and SR-BI are classic scavenger 
receptors that bind and internalize oxLDL and promote atherosclerosis through 
macrophage foam cell formation. This illuminating discovery has allowed focus to veer 
towards the investigation of other receptors and the lipids that signal through them.  
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Figure 6: Oxidized Phospholipids Present in oxPAPC and Mildly Oxidized LDL. 
Oxidation of LDL generates a variety of oxidized and fragmented phospholipids, the best 
studied of which are 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine 
(POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC) and epoxy-
isoprostane- phosphatidylcholine; 5,6-PEIPC (PEIPC). The structures of these oxidized 
phospholipids are similar and differ only in the moiety present at the sn-2 acyl chain. 
From (Leitinger, 2003). 
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Figure 7: Mass Spectrometric Output of oxPAPC. Data are represented as m/z ratio 
versus Relative Intensity (%). Peaks are indicated for POVPC at 594.3, PGPC at 610.2 
and PEIPC at 828.6. Modified from (Watson et al., 1997a).  
POVPC 
PGPC 
PEIPC 
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1.13 Short-Chain Oxidized Phospholipids 
PAF signals through a G-protein coupled receptor (PAF-R). PAF is associated with 
atherosclerosis but there is also evidence to suggest oxLDL signals through the PAF-R. 
oxLDL contains PAF-like lipids (Marathe et al., 2001). oxLDL stimulates activation of 
the PAF-R in monocytes and down-regulation of LPS-induced PAF-R expression in 
monocyte-derived macrophages (Beaudeux et al., 2004b;Hourton et al., 2001). The 
oxLDL constituent POVPC has been shown to signal through the PAF-R (Pegorier et al., 
2005). Lehr et al showed that administration of oxLDL in vivo, promoted leukocyte 
adhesion to endothelium and this was inhibited by the PAF-R antagonist WEB2170 (Lehr 
et al., 1993b). This is consistent with reports of the in vitro and in vivo inhibition of 
POVPC by WEB2170 and other PAF receptors. In the latter studies, LDL-R knockout 
mice on a Western diet were administered WEB2170 for 5 weeks showed significantly 
reduced fatty streak formation than control animals (Subbanagounder et al., 1999). 
POVPC induces monocyte binding to endothelial cells in vitro while the structurally 
similar PGPC induces adhesion of both monocyte and neutrophils (Leitinger et al., 1999). 
Furthermore, POVPC inhibits LPS-induced neutrophil adhesion to endothelial cells by 
down-regulating NF-kB-dependent transcription (Leitinger et al., 1999). Elevated 
concentrations of POVPC and PGPC (10uM or greater) initiate apoptosis by activating 
acid sphingomyelinase (Fruhwirth et al., 2006;Loidl et al., 2003). POVPC and oxPAPC 
also activate Akt and c-Src in endothelial cells leading to the uncoupling of eNOS. This 
results in the activation of the transcription factor sterol regulatory element binding 
protein (SREBP). Upon activation, SREBP binds a sterol-responsive element (SRE) in 
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the IL-8 promoter thereby increasing IL-8 transcription and thus protein (Gharavi et al., 
2006). Sphingomyelinase is the enzyme that converts sphingomyelin to ceramide, a 
potent inducer of apoptosis. Apoptotic effects of oxLDL are mimicked by ceramide in 
vascular smooth muscle cells (Loidl et al., 2004). In contrast to the apoptotic abilities of 
high-doses of short-chain oxidized phospholipids, proliferative effects are observed at 
lower concentrations. POVPC has been demonstrated to induce smooth muscle cell 
proliferation (Chatterjee et al., 2004) and vascular smooth muscle cell migration and 
collagen expression (Cherepanova et al., 2009).  
 
1.14 Long-Chain Oxidized Phospholipids 
Of the long-chain components that comprise oxPAPC, PEIPC is the best characterized. 
PEIPC binds the toll-like receptor 4 (TLR4) as well as TLR2 or components of these 
pattern recognition receptors (Erridge et al., 2008;Miller et al., 2003;Miller et al., 
2005;Walton et al., 2003b). The most recent research indicates that PEIPC binds CD14, 
LPS-Binding Protein (LBP) and MD-2 to impede LPS-signaling (Erridge et al., 2008). 
The potential for TLR4 signaling is interesting given that PEIPC interferes with signaling 
of the classic TLR4 ligand, lipopolysaccharide (LPS) (Bluml et al., 2005c;Bochkov et al., 
2002). Additionally, oxPAPC inhibits IL-8 production stimulated by the TLR2 ligand 
Pam3CSK4 oxPAPC suppresses signaling through TLR2 (Erridge et al., 2008). More 
recently, PEIPC was shown to bind the prostaglandin receptor subtypes EP2 and DP1 (Li 
et al., 2006d). The native ligands for these receptors are prostaglandin E2 (EP2) and 
prostaglandin D2 (DP1). Binding of PEIPC to EP2 initiates monocyte adhesion to 
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endothelial cells (Li et al., 2006c)). EP2 activation by PEIPC induces cyclic AMP 
mimicking the signaling effects of the selective EP2 agonist Butaprost upon this Gs-
coupled receptor (Li et al., 2006b). Interestingly, PEIPC does not bind the three other EP 
subtypes (EP1, EP3, or EP4) (Li et al., 2006e). 
 
PEIPC, POVPC and PGPC induce monocyte binding to human aortic endothelial cells in 
vitro (Subbanagounder et al., 1999). Pre-incubation of endothelial cells with the PAF-
receptor antagonist WEB-2086 inhibited PEIPC- and POVPC- but not PGPC-induced 
(Subbanagounder et al., 1999). Intriguingly, the investigators demonstrated that the PAF-
receptor was not involved in adhesion as the PAF-receptor was not detected upon 
endothelial cells and PAF itself could not reproduce the effects of the oxPL 
(Subbanagounder et al., 1999). Later studies by the same group demonstrated that 
POVPC and PEIPC induce a cAMP/R-Ras/ Phosphatidylinositol 3-kinase pathway to 
stimulate adhesion (Cole et al., 2003). In addition to these effects upon endothelial cells, 
PEIPC alone is capable of inducing IL-8 through the activation of c-src tyrosine kinase 
and signal transducers and activators of transcription 3 (Stat3) (Yeh et al., 2004).  
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Oxidized fatty acids and cholesterol 
OxPL are not the sole bioactive components of oxLDL that play a role in atherosclerosis. 
Oxidized fatty acids are believed to play a role in atherosclerosis development. 13-
hydroxyoctadecadienoic acid (13-HODE), produced by the non-enyzmatic oxidation of 
linoleic acid regulates gene expression by binding to the peroxisome proliferator-
activated receptors (PPAR) (Corton et al., 2002;Escher and Wahli, 2000). 15-HETE is a 
major product in the action of 15-lipoxygenase upon arachidonic acid. 15-HETE and 13-
HODE increase expression of CD36 by activation of PPARγ (Limor et al., 2008). 15-
HETE and 13-HODE additionally induce monocyte adhesion to endothelial cells 
(Wittwer and Hersberger, 2007). 15-HETE and 13-HODE also possess anti-inflammatory 
properties. For example, 15-HETE inhibits production of superoxide and suppresses the 
migration of neutrophils (Takata et al., 1994). Activation of PPARa and PPARg by 13-
HODE and 15-HETE reduces matrix metalloproteinase-9 (MMP-9) expression (Shu et 
al., 2000) (Marx et al., 1998). MMP-9 degrades the extracellular matrix, an event that 
contributes to the formation of the atheroma. Oxysterols are oxygenated cholesterol 
derivatives that regulate gene expression through liver X receptors (Edwards et al., 2002). 
Oxysterols are present in the atheroma and are proposed to play a part in the development 
of atherosclerosis. 27-hydroxycholesterol and 25-hydroxycholesterol are predominant 
oxysterols in the atheroma that are well studied. 25-OH induces the release of CCR7 
from murine macrophages and IL-8 in Caco-2 cells (Bai et al., 2005). 25-OH signals 
through Insig proteins and block SREBP activity but activates LXR (Radhakrishnan et 
al., 2007) (Edwards et al., 2002).  
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1.16 Periodontitis 
Periodontitis is a collective of oral inflammatory diseases. Disease onset is initiated by 
infection by an oral pathogen. Severity of the disease differs and these inflammatory 
diseases are generally characterized by the severe nature and localization of the affected 
area. Gingivitis can lead to periodontitis. Periodontal disease is caused by a group of 
predominantly gram-negative bacteria that gain access to the gingival tissue causing an 
inflammatory response, the continuation of which leads to the destruction of the 
periodontal ligament and the alveolar bone. Aggressive periodontitis (AgP) begins to 
develop in adolescents or in young adults onwards (Oh et al., 2002). This form of 
periodontitis is characterized by rapid loss of periodontal tissues (Oh et al., 2002) and is 
subdivided into localized AgP (LAgP) or generalized LAgP (GAgP). Severe destruction 
of periodontal tissues occurs in both diseases but occurs primarily around the incisors and 
primary molars in LAgP and in the other teeth in GAgP subjects (Oh et al., 2002). 
Chronic periodontitis (CP) patients are older and have slow progression of tissue loss. 
 
Aggressive Periodontitis is a multi-factorial disease. Bacteria such as Porphyromonas 
gingivalis and Aggregatibacter actinomycetemcomitans are the main etiologic factors for 
the initiation of the disease. The susceptibility of individuals to periodontitis varies 
greatly and appears to depend on a variety of risk factors. For example, age, race, gender 
and socioeconomic status are all associated background factors or determinants for AgP. 
Prevalence and severity of AgP increases with age although this is likely a result of the 
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cumulative tissue destruction that occurs over time. Individuals with African or Mexican 
heritage have a greater risk of periodontitis compared to Caucasians (Loe and Brown, 
1991). Socioeconomic status is also a factor although this may be caused by poor oral 
hygiene and other associated factors in those of lower socioeconomic status. Infection 
with other diseases has also been proposed as a risk factor. For example, patients with 
active infections of herpes simplex virus and Epstein-Barr virus have been associated 
with AgP (Imbronito et al., 2008;Saygun et al., 2004). Smoking is classically associated 
with periodontitis. GAgP and CP patients who smoke have significantly greater 
attachment loss at affected areas than non-smoking counterparts (Schenkein et al., 1995). 
Both forms of AgP appear to be inherited and can be found in the same families (Butler, 
1969;Page et al., 1985).  
 
Patients with GAgP, LAgP and CP have elevated levels of the pro-inflammatory 
phospholipid PAF present in their gingival crevicular fluid (Emingil et al., 2000). This 
has been shown to correlate with disease severity (Garito et al., 1995). Clinical treatment 
of periodontitis significantly reduces PAF levels in the crevicular fluid and improves 
periodontitis suggesting that PAF may be an important inflammatory mediator in this 
disease (Rasch et al., 1995). LAgP subjects possess low levels of PAFAH, the enzyme 
that catabolyzes PAF (Al Darmaki et al., 2003)(Figure 8) and have elevated PAF 
synthesis (Shin et al., 2007). This suggests that low levels of PAFAH and elevated PAF 
result in the persistence of the inflammation and that these factors play an important role 
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in the pathogenesis of LAgP. In addition to the atypical levels of PAFAH and PAF, the 
monocytes of AgP subjects exhibit abnormalities associated with monocytes. LAgP 
monocytes have a propensity to differentiate into DC compared to the largely 
macrophage population that arises from NP monocytes (Barbour et al., 2002c). 
Monocytes from both LAgP and GAgP subjects are hyper responsive to LPS compared to 
NP monocytes producing TNFα and PGE2 in exceedingly high quantities (Offenbacher 
and Salvi, 1999;Shapira et al., 1994).  
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Figure 8: PAFAH Activity is Lower in Subjects with LAgP Compared to NP 
Subjects. Monocytes from five LAgP (Localized Aggressive Periodontitis, previously 
known as Localized Juvenile Periodontitis) and six NP (non-periodontitis) were cultured 
in human serum for four days. PAFAH activity was quantified from cell homogenates. 
Data shown are the mean ± standard error of four subjects in each group (p<0.05). 
Modified from Al-Darmaki et al., Journal of Immunology, 2003 (Al-Darmaki et al., 
2003). 
 
*
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1.17 Periodontitis and Atherosclerosis 
Recent epidemiological data have revealed that there is an increased incidence of 
atherosclerosis in periodontitis patients (Elter et al., 2003c;Grau et al., 2004a). Both 
periodontitis and atherosclerosis are diseases of chronic inflammation. CP has been 
associated with increased risk of coronary heart disease and stroke (Beck et al., 
1996;Elter et al., 2003b). Periodontal disease has a tendency to be more severe in stroke 
patients compared to controls (Dorfer et al., 2004;Grau et al., 2004b). Measures of 
periodontitis such as periodontal pocket depth have been shown to correlate with elevated 
cholesterol and LDL levels (Emingil et al., 2000). Periodontitis has also been 
demonstrated to decrease the level, and antiatherogenic potency of HDL (Pussinen et al., 
2004). P.gingivalis infection of apoE null mice results in the exacerbation of 
atherosclerosis (Lalla et al., 2003). Chronic periodontitis is associated with elevated 
plasma concentrations of the pro-inflammatory cytokine IL-6 that is also elevated in 
atherosclerosis (Monteiro et al., 2009). Periodontal disease is also associated with the 
induction of a variety of inflammatory cytokines and mediators such as TNFα and PGE2 
that have the potential to impact upon atherosclerosis development (Offenbacher and 
Salvi, 1999;Shapira et al., 1994). Recently Rufail et al., revealed that GAgP subjects 
possess a more atherogenic lipoprotein profile than non-periodontitis (NP) subjects 
(Rufail et al., 2005). LDL particle size in GAgP patients was statistically lower than in 
NP subjects suggesting a prevalence of the atherogenic small dense LDL. These subjects 
also have lower LDL-associated PAFAH activity than non-periodontitis subjects (Rufail 
et al., 2005).  
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Antiphospholipid syndrome (APS) is an autoimmune disorder characterized with 
thrombosis and cardiovascular disease (Ames et al., 2005). It is caused by the 
autoimmune production of antibodies against phospholipid. In the general population, 
this disorder is observed in one to five percent of healthy adults (Petri, 2000), however a 
significantly larger proportion of periodontitis patients have APS (Schenkein et al., 
2003a). Anti-CL is detected in 16.2 percent of chronic periodontitis- and 19.3 percent of 
GAgP subjects (Schenkein et al., 2003b). APS is associated with antibodies against 
oxidized phospholipids and complexes of cardiolipin and β2 glycoprotein I. Anti-
cardiolipin antibodies are associated with thrombosis risk (Galli et al., 2003). C-reactive 
protein (CRP) binds oxLDL, an act that is hypothesized to mediate oxLDL opsonization 
through binding of the Fc receptor would potentially lead to the formation of foam cells. 
Periodontitis patients also have anti-cardiolipid antibodies that are largely directed 
against the complex of cardiolipin and β2-glycoprotein I (Schenkein et al., 2003b). 
Phosphorylcholine-bearing strains of oral bacteria and oxLDL react with anti-PC IgG 
from human serum (Schenkein et al., 2001). This implies that antibodies directed at 
periodontal bacteria cross-reacts with oxidized phospholipids to increase the opsonization 
of oxLDL thereby increasing foam cell formation and promoting atherosclerosis 
progression. Despite the strong correlative evidence, odds ratios demonstrate just a 
modest correlation between periodontal disease and atherosclerosis overall (Grau et al., 
2004b). However, as discussed these associations may be stronger within types of 
periodontal diseases and there are a variety of common factors between periodontitis and 
atherosclerosis. For example, treatment of periodontitis reduces the anti-atherogenic 
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potential of HDL and reduces C-reactive protein (Pussinen et al., JLR, 2004). More 
recent studies indicate that in the long-term HDL cholesterol is increased and LDL 
cholesterol decreased following periodontal treatment of periodontitis patients (Buhlin et 
al., 2009). This further underscores the link between periodontitis and atherosclerosis and 
suggests that further research is warranted. 
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CHAPTER TWO: THE REGULATION OF PLATELET ACTIVATING FACTOR 
ACETYLHYDROLASE BY OXIDIZED PHOSPHOLIPIDS 
 
   
2.1 INTRODUCTION 
 
Atherosclerosis is a chronic inflammatory disease involving lipid accumulation in the 
vessel wall (Ross, 1999). Transcytosis of Low Density Lipoprotein (LDL) to the arterial 
intima results in binding to resident proteoglycans. The oxidative modification of LDL 
that ensues generates a spectrum of bioactive oxidized phospholipids (oxPL) (Tsoukatos 
et al., 1997). 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) is the 
most abundant arachidonyl-containing phospholipid present upon the LDL particle 
(Podrez et al., 2002a). Oxidized PAPC (oxPAPC) is a component of minimally modified 
LDL that has been measured in atherosclerotic lesions (Subbanagounder et al., 1999) and 
characterized extensively with respect to its proatherogenic biological activities (Birukov 
et al., 2004b;Huber et al., 2006;Lee et al., 2000).  oxPAPC comprises numerous bioactive 
lipid mediators notably 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine 
(POVPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) and epoxy-
isoprostane-PC (PEIPC) (Leitinger, 2003;Subbanagounder et al., 2002c). OxPAPC and 
its constituents have been shown to mediate many pro-atherogenic events including 
adhesion, chemotaxis and differentiation of monocytes (Frostegard et al., 1997a) and 
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activation of endothelial cells (Subbanagounder et al., 1999;Yeh et al., 2004). These 
events and the subsequent uptake of oxidized LDL (oxLDL) by monocyte-derived cells 
represent the earliest events in atherosclerosis (Matsuura et al., 2006). 
 
Platelet activating factor acetylhydrolase (PAFAH) is a phospholipase A2 enzyme that 
catabolyzes the pro-inflammatory lipid platelet activating factor (PAF) and oxPL with 
short-chain moieties at the sn-2 position. PAFAH is produced by monocyte-derived cells; 
macrophages (MO) and dendritic cells (DC) (Al Darmaki et al., 2003). Following release 
from the cell, PAFAH associates with LDL and hence has been given the name 
lipoprotein-associated phospholipase A2 (LpPLA2). Although PAFAH catabolizes 
proatherogenic oxLDL and oxPL, the products of the PAFAH reaction are also 
proinflammatory and can exacerbate atherosclerosis (Ninio et al., 2004c). There is 
considerable evidence that PAFAH correlates with increased incidence and severity of 
coronary artery disease (Stafforini et al., 1987a;Stafforini et al., 1997a). PAFAH is 
strongly expressed in the early atheroma but is relatively low in advanced lesions 
(Kolodgie et al., 2006). Phase III clinical trials of the inhibitor Darapladib demonstrate 
that suppression of the PAFAH activity results in a transient decrease in circulating CRP 
and IL-6 and also reduces necrotic core progression (Wilensky et al., 2008). These data 
suggest that PAFAH plays an important role in the progression of atherosclerosis.  
 
Despite significant evidence linking PAFAH to atherosclerosis, signaling mechanisms 
that induce PAFAH in disease remain elusive. The PAFAH promoter contains a proximal 
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putative GAS sequence that could be targeted by pro-inflammatory cytokines (Cao et al., 
1998c). PAFAH transcription is induced by lipopolysaccharide (LPS), likely through 
both Sp1 and transcription factors activated by LPS-induced proinflammatory cytokines 
(Wu et al., 2004). PAF stimulates PAFAH transcription in HEK cells stably expressing 
the PAF-R (Cao et al., 1998b). Some species of oxPL are “PAF-like” because they are 
substrates for PAFAH and bind the PAF receptor. As oxPL are co-localized with 
PAFAH-producing monocyes in developing atheromas, we hypothesized that the high 
levels of PAFAH in atherosclerosis are a consequence of oxPL-induced PAFAH 
production.  
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2.2 MATERIALS AND METHODS 
 
2.2.1 Materials 
Buffy coat was purchased from Virginia Blood Services (Richmond, VA). THP-1 human 
monocytes were purchased from the American Type Culture Collection (Manassas, VA). 
oxPAPC and its fractions were prepared as described previously (Birukov et al., 2004a)). 
IL-6, M-CSF, GM-CSF and IL-4 were all from RnD Systems (Minneapolis, MN). [3H-
]PAF was purchased from New England Nuclear/PerkinElmer (Boston, MA). 1-alkyl-2-
acetyl-sn-glycero-3-phosphocholine (PAF), 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-
3-phosphocholine  (POVPC), 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine  
(PGPC) and 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC) were 
purchased from Avanti Polar Lipids (Alabaster, AL). AH6809 was purchased from 
Biomol (Plymouth Meeting, PA). Lipopolysaccharide (LPS) and Fetal Calf Serum were 
purchased from Sigma (St Louis, MO). Human Serum was from Cambrex (Walkersville, 
MD). Lymphocyte separation medium was from MP Biomedicals (Solon, OH). 
Butaprost, BW245C, BWA868C and PAFAH antibody were purchased from Cayman 
Chemicals (Ann Arbor, MI). RT-PCR primers were purchased from Integrated DNA 
Technology (Coralville, IA). ERK1/2 antibody was purchased from Cell Signaling 
(Danvers, MA).   
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2.2.2 THP-1 Monocyte Culture 
THP-1 human monocytes were maintained in RPMI with 10% Fetal Calf Serum with 
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. THP-1 monocytes 
were maintained between 2x105/ml and 1x106/ml, were fed approximately every two 
days and passaged at least once a week. Cells were passaged to 2x105/ml the day 
previous to treatment with viability at the onset of experiments typically greater than 
98%. Cells were maintained under standard cell culture conditions at 37°C and 5% CO2 
and were stimulated in serum-free media.  
 
2.2.3 Primary Cell Culture and Differentiation  
Approximately 40ml of Buffy coat was diluted with 40ml RPMI. Diluted buffy coat was 
layered on a ficoll gradient then centrifuged for 30 minutes at 300g at 20°C. The fuzzy 
mononuclear layer was washed three times with RPMI and centrifugation at 1500g for 10 
minute washes. Each time the supernatant was removed and the pellet washed again. 
After three washes the pellet was resuspended in RPMI supplemented with 10% Human 
AB Serum. Cells were plated at a density of 107 per well in 6 well plates and incubated 
for 1-2 hours at standard cell culture conditions. Supernatant and non-adherent cells were 
removed and monolayer was washed 3 times with plain RPMI. Monocytes were treated 
in serum-free media at this point. Other monocytes were induced to differentiate with 
cytokine for 7 days into DC with 800U/ml GM-CSF and 500U/ml IL-4 in RPMI with 
10% Fetal Calf Serum or into Macrophages with 1000U/ml M-CSF in RPMI with 10% 
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Human Serum. Macrophage and Dendritic cell RPMI media was also supplemented with 
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. 
 
2.2.4 Isolation of Low-Density Lipoprotein  
Human peripheral blood was drawn after an overnight fast and collected in five, 10ml BD 
vacutainers with K3 EDTA. Blood was divided equally into two centrifuge tubes and 
centrifuged at 3,000g for 20min at 4°C. Plasma was collected after this first 
centrifugation and was supplemented with 500ul Protease I inhibitor NaN3 (0.02%) and 
EDTA (1mM). Plasma was mixed with stock density solution then transferred to two 
centrifuge tubes. An overlay of stock density solution was added to the tube. Samples 
were centrifuged at 45,000rpm at 20°C for 20 hours. After the first centrifugation, the 
upper cloudy layer of VLDL was removed. The infranatant density was checked using a 
refractometer to ensure it was between 1.015 and 1.017. Once this certain, the remaining 
infranatant was removed and the pellet resuspended. Stock density solution was added 
and the overlay added over the top. Samples were centrifuged for a further 45,000rpm at 
20°C for another 20 hours. At the end of this time, the upper cloudy layer of LDL was 
removed from the tubes. Density of infranatant was checked as 1.063 then LDL stored 
under argon/nitrogen at 4°C until use.  
 
2.2.5 Protein Assay of Low Density Lipoprotein  
Protein concentration was determined using a modified Lowry method with a BSA 
standard (Miwa et al., 1988). Reagent A was made with 20ml CTC reagenet, 40ml 5% 
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SDS solution and 20ml 0.8M NaOH. Reagent B was Folin Reagent diluted 1:6 with H20. 
Dialyzed LDL or BSA were incubated with 0.5ml Reagent A for 10 minutes at room 
temperature. Then 0.25ml Reagent B was added, mixed and incubated at room 
temperature for 30 minutes. At this point absorbance was measured in a 
spectrophotometer at 750nm against blank.  
 
2.2.6 Oxidation of Low Density Lipoprotein 
LDL was dialyzed before oxidation or before incubation with cell cultures using dialysis 
membrane in phosphate buffered saline with a stir bar present overnight in a cold room. 
LDL was preserved in its native form (nLDL) or oxidized by exposure to air or with 
2.5μM CuS04 as described previously (Anthonsen et al., 2000b) to produce oxidized LDL 
(oxLDL). LDL preparations were supplemented with NaN3 and EDTA post-oxidation to 
preserve and protect against further modification. Conjugated dienes were determined by 
spectrophotometric analysis of 50µg/ml LDL preparations at 234nm (nLDL<0.1, 
mmLDL=0.2, moxLDL=0.4, oxLDL=0.6, soxLDL=1.0). LDL was extensively dialyzed 
against PBS before incubating with cells. Cell cultures were treated with 50μg/ml LDL 
for 16 hours. 
 
2.2.7 Platelet Activating Factor Acetylhydrolase Activity Assays  
Substrate consisted of 50uM 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine with 0.05 µCi 
of hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine, 1-O-[acetyl-(N)-3H] 
(NEN/PerkinElmer; 13.5 Ci/mmol) added as a tracer. Substrate was incubated with 
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conditioned medium (enzyme source) and incubated for 30 minutes at 37°C. PAFAH 
activity was determined as release of [3H] acetate as quantified by scintillation counting. 
 
2.2.8 RNA Isolation and Platelet Activating Factor Acetylhydrolase Quantitative 
Real-Time PCR  
RNA was isolated with the Trizol reagent (Invitrogen). PAFAH specific primers were 
used to amplify product and normalized to 18S rRNA. PAFAH mRNA was measured by 
quantitative real time PCR (qPCR). PAFAH and 18S specific primers and Taqman 
probes were as follows; PAFAH probe 5’atgatcgccttgacaccctttgga-3’, sense 
5’tgcgtttatattatccatcccaa-3’ and antisense 5’agttgtcattgcaccaaagagt-3’. 18S probe 
5’cgagccgcctggataccgcagc-3’, sense 5’aaaattagagtgttcaaagcaggc-3’ and anti-sense 
5’cctcagttccgaaaaccaacaa-3’. In IL-6 qPCR experiments cDNA was generated using the 
High Capacity RNA to cDNA kit from ABI. The IL-6 Gene Expression Assay kit was 
used to quantify IL-6 mRNA. All real time PCR reactions were performed with the 
TaqMan® One-Step kit from ABI on an ICycler instrument from BioRad.  
 
2.2.9 Reverse Transcriptase PCR 
Total RNA isolated with the Trizol reagent (Invitrogen) was used to make cDNA using 
the ThermoScript kit from Invitrogen. cDNA was subjected to 30 cycles of PCR 
amplification (EP2: 94°C 30seconds, 58°C 30 seconds, 68°C 1 minute. DP1: 94°C 30 
seconds, 62°C 30 seconds, 68°C 1min) using the Invitrogen Accuprime Taq DNA 
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Polymerase Kit. RT-PCR Products were analyzed using agarose gel electrophoresis. 
Expected product sizes were as follows: EP2 175bp, DP1 284bp. 
 
2.2.10 siRNA experiments  
THP1 monocytes cultured in antibiotic-free RPMI prior to all siRNA experiments. 5 x 
105 THP1 monocytes in plain RPMI were seeded in 24 well plates. Cells were transfected 
with 100nmol IL-6 pool siRNA or non-targeting pool siRNA and Lipofectamine 2000 as 
per manufacturer’s instructions (1ul per treatment). Cells were incubated for 16 hours 
then supplemented with serum to 10%. Serum was withdrawn 8 hours later and indicated 
stimuli were added to the wells and incubated for a further 16 hours before harvesting.  
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Sense 5’tgcgtttatattatccatcccaa-3’ 
Anti-Sense 5’agttgtcattgcaccaaagagt-3’ PAFAH  
Probe 5’atgatcgccttgacaccctttgga-3’ 
Sense 5’aaaattagagtgttcaaagcaggc-3’ 
Anti-Sense 5’cctcagttccgaaaaccaacaa-3’ 18S 
Probe 5’cgagccgcctggataccgcagc-3’ 
Sense 5’tcgggaagttcgtgcagtactgcc-3’ 
DP1 
Anti-Sense 5’gatccagctcctccaggggctgag-3’ 
Sense 5’caacctcatccgcatcgacc-3’ 
EP2 
Anti-Sense 5’Caaggagcagacggcgaagg-3’ 
 
 
Table 4: Primer and Probe Sequences 
 
    63
2.2.11 Western Blots  
Cells were washed once with PBS then homogenized in RIPA buffer with protease 
(Roche Complete Mini) and phosphatase inhibitors. Equal amounts of protein were 
separated by SDS-polyacrylamide gel electrophoresis, blocked in 5% non-fat dried milk, 
and incubated overnight in primary antibody. Blots were developed with HRP coupled 
secondary antibodies and the enhanced chemiluminescent (ECL) detection kit 
(Amersham Bioscience) or Femto (Pierce).  
 
2.2.12 Il-6 ELISA  
IL-6 ELISA kit from BD was followed as per manufacturer’s instructions with neat 
supernatants from oxPL-treated cells.  
 
2.2.13 Flow Cytometry 
Differentiated macrophages or dendritic cells or THP1 monocytes were incubated and 
stained with PE-anti-IL-6R or PE-anti-isotype matched control for 30 minutes at 4°C. 
Cells were washed three times in PBS then analyzed using the FACScan (Becton 
Dickinson) instrument.  
 
2.2.14 Statistical Analyses  
Data are presented as mean +/- standard deviation. Student t-tests were performed and 
statistical significance is expressed as *P<0.05, **P<0.01, ***P<0.001. 
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2.3 RESULTS 
 
2.3.1 Oxidized Phospholipids Induce Platelet Activating Factor Acetylhydrolase in 
Monocytes and Dendritic Cells but not Macrophages 
 
Other investigators have demonstrated that oxidized 1-palmitoyl-2-arachidonyl-sn-
glycero-3-phosphocholine (oxPAPC) activates monocytes and induces expression of 
proinflammatory cytokines (Furnkranz et al., 2005d;Yeh et al., 2004). We sought to 
determine whether oxPAPC would also stimulate PAFAH expression. To test this 
hypothesis monocytes and monocyte-derived cells were treated with native PAPC or 
oxPAPC and PAFAH expression analyzed by quantitative RT-PCR. Native PAPC had no 
effect on PAFAH expression but LPS, a well-known inducer of PAFAH strongly 
elevated PAFAH mRNA in primary monocytes, the THP-1 human monocytic cell line 
and monocyte-derived dendritic cells (DC) and macrophages (MO) (Figure 9). In 
contrast, although oxPAPC robustly induced PAFAH expression by THP-1 monocytes 
(5.7-fold, p<0.001), primary monocytes (2.4-fold, p<0.05), and DC (2.6-fold, p<0.01), 
MO were unresponsive to oxPAPC with no significant change in PAFAH expression or 
activity (Figures 9D, 9F).  Like primary monocytes and DC, THP1 monocytes were 
highly responsive to both LPS and oxPAPC. Therefore, THP1 monocytes were used as a 
surrogate for primary cells to avoid subject-to-subject variation in the response to 
oxPAPC. 
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Figure 9: Oxidized Phospholipids Induce Platelet Activating Factor Acetylhydrolase 
in Monocytes and Dendritic Cells but not Macrophages. Cells were treated for 16 
hours with 50µg/ml PAPC, 50µg/ml oxPAPC or 100ng/ml LPS and PAFAH quantified 
by qPCR (A-D) in (A) THP-1 monocytes, (B) primary human monocytes (C) dendritic 
cells and (D) macrophages. PAFAH catalytic activity was analyzed in (E) dendritic cells 
and (F) macrophages. Responses relative to control treatments were determined and data 
represent the mean of 3-5 independent experiments. *p<0.05, **p<0.01, ***p<0.001. 
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2.3.2 PEIPC-Rich Fractions of oxPAPC Induce PAFAH Expression and Activity  
 
 
OxPAPC is comprised of an array of lipid species that differ in the degree of oxidation/ 
fragmentation of the sn-2 acyl-chain as well as their effects on monocytes and other cells 
(Bluml et al., 2005b;Leitinger et al., 1997;Pegorier et al., 2005;Yeh et al., 2004). To 
identify the species responsible for PAFAH induction, oxPAPC was separated on the 
basis of sn-2 acyl chain length into fractions designated as short-chain (m/z <782.7, rich 
in PAF-like lipids) or long-chain (m/z > 782.7, enriched with PEIPC and other 
epoxyisoprostanes). The short chain fraction had no effect on PAFAH expression in 
THP1 monocytes or DC but long chain oxPAPC lipids induced PAFAH expression by 
approximately 5-fold in DC and 2.5-fold in THP1 monocytes (Figure 10A). As predicted, 
neither short- or long-chain fractions of oxPAPC altered PAFAH expression in 
macrophages (Figure 10A). DC were also stimulated with purified components of the 
short-chain oxPAPC fraction; POVPC and PGPC (Figure 10B). POVPC did not 
significantly alter PAFAH expression from control levels (Figure 10B). PGPC 
significantly induced PAFAH expression, however this was modest at best (~1.8-fold, 
p=0.04) and could account for the robust induction of PAFAH expression that was 
observed following oxPAPC stimulation. The strong PAFAH induction in DC in 
response to 10µg/ml long-chain oxPAPC lipids led us to further investigate the sensitivity 
of these cells to long-chain oxPAPC. As little as 5ng/ml of the long-chain fraction of 
oxPAPC was sufficient to significantly induce DC PAFAH expression (Figure 10C). This 
series of experiments also revealed that the sensitivity of DC to long-chain lipids is not 
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constant. The experiment in Figure 2C reveals a maximal induction of PAFAH at 
0.5µg/ml (approximately 4-fold) in comparison to 10µg/ml in Figure 10A (approximately 
5-fold). The maximum fold induction observed between these series of experiments is, 
however comparable. To further emphasize the role of PEIPC in the induction of 
PAFAH, UV-treated PAPC was used as an independent test. Treatment of PAPC with 
UVA-1 (340-390nm) is an alternative method by which to produce a lipid fraction that is 
rich in PEIPC (Gruber et al., 2007). DC treated with 2µg/ml or 10µg/ml UV-PAPC for 16 
hours responded with a significant induction of PAFAH (1.96-fold at 2µg/ml; Figure 
10C). 
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Figure 10: Long-chain Oxidized Phospholipids Induce PAFAH Expression. A. DC, 
THP-1 Monocytes and Macrophages were treated with short- or long-chain fractions 
derived from 10µg/ml oxPAPC for 16 hours. B. DC were treated with 10µM POVPC or 
PGPC for 16h then PAFAH expression was quantified from RNA. C. DC were treated 
with various concentrations of long-chain fractions of oxPAPC for 16 hours D. Dendritic 
cells were stimulated with PEIPC-containing fractions of lipids prepared by UV-
oxidation at either 2µg/ml or 10µg/ml for 16 hours. PAFAH expression is expressed as 
fold relative to vehicle control. Responses relative to control treatments were determined 
and data are the mean of 3 independent experiments (A-C) or a single experiment (D). 
*p<0.05, **p<0.01, ***p<0.001. 
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2.3.3 Signaling through EP2 and DP1 are required for PAFAH induction by Long 
Chain oxPAPC 
 
PEIPC, the best characterized of the long-chain species of oxPAPC (Subbanagounder et 
al., 2000;Subbanagounder et al., 2002b), binds the prostaglandin receptors DP1 and EP2 
(Li et al., 2006a);. As shown in Figure 11A, both of these receptors are expressed by 
monocytes and monocyte-derived DC and MO. We next tested the hypothesis that 
oxPAPC induces PAFAH through DP1 and/or EP2. THP-1 monocytes and DC were 
incubated with selective agonists for EP2 (Butaprost, Figure 11B-C) or DP1 (BW245C, 
Figure 11E-F). Both agonists induced PAFAH in THP1 cells and DC in a dose-
dependent manner. Treatment of macrophages with 1uM Butaprost did not elicit a 
response (Figure 11D). In addition, a selective antagonist of DP1 suppressed oxPAPC-
mediated induction of PAFAH by greater than 75% (Figure 11G). Together, these data 
suggest that long chain lipids in oxPAPC induce PAFAH primarily through the 
prostaglandin receptors EP2 and DP1.    
    70
 
 
 
Figure 11: Prostaglandin Receptor Subtypes DP1 and EP2 are Required for 
Optimal PAFAH Induction by long-chain oxidized phospholipids. A. EP2 and DP1 
expression was measured by reverse transcriptase PCR. Data shown is representative of 3 
independent experiments. B-F PAFAH expression was analyzed in THP-1 monocytes 
following 16 hour treatments. B. THP1 Monocytes were treated with 0.01, 0.1 or 1uM 
Butaprost. C. DC were treated with 0.01, 0.1 or 1uM Butaprost. D. Macrophages were 
treated with 1uM Butaprost. E. DC were treated with BW245C. F. THP-1 Monocytes 
were treated with BW245C. Responses are expressed relative to control treatments. 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 11: Prostaglandin Receptor Subtypes DP1 and EP2 are Required for 
Optimal PAFAH Induction by long-chain oxidized phospholipids G.THP1 monocytes 
were pre-treated with 0.01, 0.1, 1uM BW A868C (G) or 10uM AH6809 (H) for 30 
minutes before stimulation with 10µg/ml long-chain fraction of oxPAPC. Cells were 
harvested at 16 hours and PAFAH expression quantified. Results are expressed as the 
percentage of optimal PAFAH induction where “0” treatment is treatment with long-
chain oxpapc fraction in the absence of inhibitor. The mean of two independent 
experiments ± std dev is shown. *p<0.05, **p<0.01, ***p<0.001. 
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2.3.4 IL-6 Induces PAFAH Expression 
 
The PAFAH 5’ flanking region contains a canonical γ-interferon activation site (GAS) 
sequence (598TTCAGAGAA606) that has the potential to bind the transcription factor Stat 
3. Several recent reports have shown that prostaglandin E2 (PGE2) induces interleukin 6 
(IL6) production and/ or augments STAT3 activation by IL6 (Cheon et al., 2006a;Han et 
al., 2006b;Liu et al., 2002c). Butaprost, the selective EP2 agonist, induces IL-6 
production by macrophages (Chen et al., 2006) and our data demonstrate that IL-6 is 
induced by the selective DP1 agonist BW245C as well (Figure 12A). Based on these 
studies, we hypothesized that PAFAH induction by oxPAPC would be mediated through 
IL-6. To test this hypothesis, we first performed experiments to determine if the oxPL 
induce IL-6. The long-chain fraction of oxPAPC stimulated IL-6 production by THP1 
monocytes (Figure 12A). Exogenous IL-6 mimicked the effects of oxidized lipids and 
induced PAFAH expression by ~2-fold which was comparable to induction by the 
canonical PAFAH inducer LPS (Figure 12B). IL-6 also induced PAFAH in a time-
dependent manner in THP1 monocytes and DC (Figure 12D and F). Importantly, 
oxPAPC and in particular long-chain fractions stimulate IL-6 production in a manner that 
precedes that of PAFAH (Figure 12C-E). Together, these data support the hypothesis 
that IL-6 is upstream of PAFAH induction in oxPAPC-stimulated monocytes. To confirm 
this hypothesis, we quantified PAFAH expression in oxPAPC-stimulated THP1 cells that 
were pretreated with siRNA directed against IL-6 (Figure 12F). IL-6 siRNA significantly 
suppressed induction of PAFAH by the long-chain fraction of oxPAPC (Figure 12E, p = 
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0.03; n=2).  These data demonstrate that IL-6 is required for optimal PAFAH expression 
in response to oxPAPC.  
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Figure 12: Interleukin 6 Induces PAFAH Induction. A. Dendritic cells were treated 
with BW245C 0.1υM or oxPAPC 10µg/ml for 16hours. Secreted IL-6 protein was 
measured using ELISA. Relative IL-6 secretion is shown as fold to vehicle control. B. 
THP-1 monocytes were stimulated with exogenous IL-6 for 3- or 6-hours and PAFAH 
expression quantified. C. THP-1 monocytes were stimulated with long-chain fractions of 
oxPAPC over 48 hours before PAFAH expression was quantified. D. THP-1 monocytes 
treated with 10µg/ml short-chain or long-chain fractions of oxPAPC for 16 hours were 
analyzed for IL-6 expression via qPCR. Responses relative to control treatments were 
determined and data represent the mean of 3 (A-D) Data in Panel B was generated by 
Minkyeong Son, Experiment in Panel D was conducted by Minkyeong Son from samples 
generated by Rachael Griffiths. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 12: Interleukin 6 Induces PAFAH Induction. E. THP-1 monocytes treated with 
siRNA directed against IL-6 were stimulated with 10µg/ml oxPAPC. PAFAH expression 
was analyzed at 16 hours. F. DC treated with oxPAPC over a 48h period were harvested 
and IL-6 secretion and PAFAH expression analyzed. Responses relative to control 
treatments were determined and data represent the mean 2 independent experiments (E), 
or a single experiment (F). *p<0.05. 
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2.3.5 IL-6 Receptor Expression May Limit PAFAH Induction in Macrophages 
 
While oxPAPC upregulates PAFAH in monocytes and monocyte-derived DC, MO do not 
respond in this manner (Figure 9D,9F and 9B). This observation suggests that 
macrophages lack an essential component of the signaling machinery necessary to make 
this response. As illustrated in Figure 11A, MO express DP1 and EP2, the prostaglandin 
receptors that bind long chain lipids in oxPAPC and induce PAFAH. Therefore, we 
focused our attention on events downstream of prostaglandin receptors and performed 
experiments to compare IL-6 receptor (IL-6R) expression in MO and DC. As shown in 
Figures 13A-C, cell surface expression of IL6-R was considerably lower on MO in 
comparison to THP-1 monocytes and DC. To confirm these data, we compared IL-6 
receptor expression in whole cell homogenates by Western blot. While IL6-R was readily 
detected in homogenates of DC and THP cells, we were unable to detect IL-6R in 
macrophage homogenates (Figure 13D). Importantly, although PAFAH was readily 
induced when THP1 monocytes or DC were stimulated with exogenous IL-6, MO 
responded more modestly (Figure 13E). These data suggest that the ability of MO to 
induce PAFAH in response to oxPAPC is limited by their low expression of IL6-R.   
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2.3.6 The Induction of PAFAH by oxPAPC May Be Mediated by Stat3 
 
IL-6 binding to its receptor leads to the activation of Signal Transducer and Activator of 
Transcription 3 (Stat3) (Han et al., 2006a). PAFAH contains a canonical Stat-binding 
GAS element and could therefore be transcriptionally regulated by Stat. We next tested 
whether Stat3 was involved in the regulation of PAFAH by oxPAPC. DC were treated 
with oxPAPC over 8 hours and the activation of Stat3 was assessed at various times by 
measuring phosphorylation of this transcription factor. Stat3 tyrosine and serine 
phosphorylation was elevated at 4 hours in DC treated with oxPAPC versus vehicle 
(Figure 13F) suggesting that Stat3 is activated by oxPAPC. 
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Figure 13: Interleukin 6 Signaling May be Required for the Oxidized Phospholipid 
Mediated Expression of PAFAH. THP-1 monocytes (A), Dendritic Cells and (B) and 
Macrophages (C) were incubated with PE-IL-6 Receptor antibodies or IMC and assessed 
by flow cytometry. Histograms show relative fluorescence against events for unlabeled 
cells (grey open trace), IMC (black open trace) or IL-6 Receptor (grey closed trace). 
D.Macrophages, Dendritic cells and THP-1 monocyte protein homogenates were used to 
quanitify relative IL-6R expression by Western blot analysis. Representative blots are 
shown of IL-6R (upper) protein with loading control for ERK1/2 (lower). E. Supernatants 
of macrophages (grey bars) and DC (black bars) treated with recombinant IL-6 were 
assayed for PAFAH activity. Relative levels of PAFAH activity are shown. F. Stat3 
phosphorylation (Tyrosine or Serine) status was analyzed relative to total Stat3 in protein 
homogenates of DC treated with oxPAPC over a period of 8 hours. Responses relative to 
control treatments were determined and data represent the mean of 3 independent 
experiments (A-E) or a single experiment (F). Data in Panel E was generated by 
Muralikrishna Mukkamala. *p<0.05, **p<0.01, ***p<0.001. 
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2.3.7 Mildly Oxidized LDL Induces PAFAH Expression  
 
PAPC is the most abundant arachidonyl-containing phospholipid in LDL and the major 
oxidized phospholipid species associated with oxPAPC have been identified in a mildly 
oxidized LDL (Watson et al., 1997a). We next performed experiments to determine 
whether LDL-associated oxPL would induce PAFAH. LDL-associated PAFAH activity 
was first inhibited using Pefabloc (Figure 14A). Excess inhibitor and salts were removed 
by dialysis, then oxidized preparations of LDL were generated by incubating native LDL 
with air or CuS04 at 37oC (methods). Five species of LDL were produced that ranged in 
their oxidation level from native, or unmodified (nLDL) to extensively oxidized 
(eoxLDL). The range of oxidation levels was measured by analyzing conjugated diene 
formation at 234nm (Figure 14B). Preliminary experiments revealed a mildly oxidized 
LDL preparation was the sole species generated that could significantly alter PAFAH 
expression (Figure 14C). Further research revealed that this species of oxLDL 
significantly induced PAFAH expression in monocyte-derived DC but not in MO. These 
observations are consistent with effects of oxPAPC on PAFAH expression in MO and 
DC (Figure 9) and supported the hypothesis that oxLDL-associated oxPL induce 
PAFAH in early atheromas.  
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Figure 14: Oxidized LDL Induces PAFAH Expression in Dendritic Cells and not 
Macrophages. A. LDL-associated PAFAH Activity was Inhibited with Pefabloc. B. LDL 
was oxidized to varying degrees (see methods for details) and Oxidation quantified at 
234nm. Results are representative C. Differentiated AgP Monocytes were incubated with 
50µg/ml of LDL species for 16h before PAFAH expression was analyzed. D. DC and 
Macrophages were incubated with 50µg/ml Oxidized LDL for 16 hours and PAFAH 
expression was quantified by qPCR. Responses relative to control treatments were 
determined. *p<0.05, **p<0.01. 
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Figure 15: Model of Long-Chain oxPL Regulation of PAFAH Expression  
OxPAPC and its constituent PEIPC are present upon oxLDL particles. These oxPL bind 
the prostaglandin receptor subtypes EP2 and DP1 triggering the induction of IL-6 
expression. IL-6 protein is secreted from the cell and binds its receptor (IL-6R). This 
activates Stat3 allowing its translocation to the nucleus and binding to GAS element in 
the PAFAH 5’ region. We hypothesize that this initiates PAFAH transcription and hence 
increased PAFAH protein.  
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2.4 DISCUSSION 
 
OxPAPC and other oxPL have a variety of effects that are central to the development and 
progression of atherosclerosis including activation of endothelial cells, smooth muscle 
cells and macrophages (Cherepanova et al., 2009;Pegorier et al., 2005;Subbanagounder et 
al., 2002a). Our studies are the first to demonstrate that oxPAPC induces PAFAH, the 
lipoprotein-associated PLA2.  OxPAPC and its component lipids were originally 
identified in a mildly oxidized preparation of LDL (Watson et al., 1997a). We 
demonstrate that mildly oxidized LDL induces PAFAH to levels comparable to those 
achieved with oxPAPC. Importantly, our data suggest that oxPAPC and oxLDL induce 
PAFAH through similar mechanisms, as monocytes and DC respond to both stimuli but 
neither oxPAPC nor oxLDL induce PAFAH in macrophages. Together, these data 
underscore the physiological relevance of oxPAPC-mediated PAFAH induction and 
support the hypothesis that oxLDL-activated monocytes are responsible for the high 
levels of PAFAH in atherosclerosis.  
 
Other investigators have shown that PAF induces transcriptional activity of a PAFAH 
reporter construct in COS cells (Cao et al., 1998a). Based on those observations, we 
hypothesized that PAF-like lipids in the short chain fraction of oxPAPC would induce 
PAFAH. Contrary to our expectations, short chain, PAF-like lipids have no effect on 
PAFAH. The short chain fraction contains a variety of lipid species, only some of which 
are PAF-like and bind the PAF receptor (Pegorier et al., 2005). It is possible that other 
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lipids in the short chain fraction antagonize effects of PAF-like lipids resulting in no net 
increase in PAFAH expression. Alternatively, PAF-mediated induction of PAFAH may 
be cell-type specific.  
 
Our studies indicate that lipids in the PEIPC-containing long-chain fraction of oxPAPC 
induce PAFAH. These lipids bind a variety of receptors, including the VEGF receptor, 
toll-like receptors, and the prostaglandin receptors EP2 and DP1 (Li et al., 2006a;Walton 
et al., 2003a;Zimman et al., 2007). As monocytes express EP2 and DP1 and are known to 
be activated by prostaglandins (Hata and Breyer, 2004), we tested the hypothesis that the 
long chain fraction of oxPAPC induces PAFAH through these receptors. Both EP2 and 
DP1 agonists induced PAFAH expression. Conversely, oxPAPC-mediated PAFAH 
induction was suppressed by a DP1 receptor antagonist. Neither inhibitor completely 
blocked PAFAH induction, suggesting that both prostaglandin receptors are involved in 
this response to oxPAPC. Together, these studies indicate that monocytes produce 
PAFAH in early atheromas when they are activated by epoxyisoprostanes from mildly 
oxLDL.  
 
EP2 and DP1 are G protein-coupled receptors that signal through Gs and activate 
adenylyl cyclase and other signaling pathways (Hata and Breyer, 2004). Like 
prostaglandins, the long chain oxPL PEIPC augments cytosolic cAMP (Cole et al., 2003). 
Although these observations suggest that oxPAPC increases PAFAH transcription 
through CREBP, there is no evidence for a cyclic AMP response element (CRE) in the 
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PAFAH 5’ flanking region. Prostaglandin E2 (PGE2) and synthetic EP2 agonists induce 
interleukin 6 (IL6) production and/ or augment STAT3 activation by IL6 (Chen et al., 
2006;Cheon et al., 2006b;Han et al., 2006c;Liu et al., 2002b). Other investigators have 
shown that oxPAPC and oxidized surfactant lipids stimulate interleukin-6 (IL-6) 
production and PEIPC activates Stat3, a transcription factor in the IL-6 signaling pathway 
(Furnkranz et al., 2005d;Imai et al., 2008;Yeh et al., 2004). These observations prompted 
the hypothesis that IL-6 is involved in oxPAPC-mediated PAFAH induction. We report 
several lines of evidence supporting this hypothesis, including (a) monocytes generate IL-
6 in response to stimulation with oxPAPC or the prostaglandin receptor agonists 
butaprost and BW245C, (b) IL-6 production precedes that of PAFAH, (c) PAFAH 
expression increases when monocytes are treated with exogenous IL-6, and (d) IL6-
targeted siRNA reduces oxPAPC-mediated PAFAH induction. These observations are 
consistent with other reports that IL-6 is required for optimal responses to oxPAPC 
(Furnkranz et al., 2005b;Van Lenten et al., 2001b). Notably, the IL-6 5’ flanking region 
contains a canonical GAS element (1052-TTCTTGGAA-1060) that could bind activated 
Stat3 and our preliminary data indicate that Stat3 is tyrosine- and serine-phosphorylated 
in oxPAPC-treated cells (Figure 13). At present, we are performing additional 
experiments to delineate the roles of Stat3 and the GAS element in PAFAH induction by 
oxPAPC. 
 
Monocytes and DC robustly induce PAFAH in response to oxPAPC.  However, 
macrophages did not make this response and their failure to respond was not due to a lack 
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of the prostaglandin receptors EP2 or DP1. Although exogenous IL-6 robustly induced 
PAFAH in DC, macrophages made a more limited response which prompted the 
hypothesis that oxPAPC-mediated PAFAH induction is limited in these cells due to low 
expression of IL-6 receptor. Indeed macrophages express almost undetectable levels of 
IL-6Rα (Figure 13C). Although MO likely do not secrete significant amounts of PAFAH 
in response to oxLDL in early atheromas, it remains possible that they contribute to this 
response. MO are activated in response to signaling through the prostaglandin receptors. 
As noted above, these receptors signal through adenylate cyclase, leading to increased 
cytosolic cAMP. The IL-6 promoter contains a cAMP-responsive element (CRE) and 
cAMP is known to induce IL-6 production by monocytes (Dendorfer et al., 1994). Thus, 
it is possible that oxPL-activated MO augment PAFAH production by producing IL-6. 
Additional experiments are required to test this hypothesis and further delineate the roles 
of MO and DC to PAFAH production in atherosclerosis.  
 
Although both monocytes and DC generate PAFAH in response to oxPL, DC are unique 
in their ability to produce large amounts of PAFAH in response to IL-6 as well. Like 
PAFAH, IL-6 expression is elevated in atherosclerosis lesions (Seino et al., 1994).  We 
hypothesize that high levels of IL-6 in the atheroma exacerbate effects of oxPL resulting 
in chronic activation of DC and the high levels of PAFAH that characterize 
atherosclerosis. This is a unique role for DC in the pathogenesis of atherosclerosis, but it 
adds to a growing list of studies suggesting that DC may be more important components 
of the atheroma than was previously believed. Like macrophages, (the monocyte more 
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classically associated with atherosclerosis), immature DC are highly phagocytic and can 
engulf large amounts of oxLDL and may become foam cells (Albert et al., 1998). DC are 
present at unstable shoulder regions of the plaque (Bobryshev, 2000a) and are proposed 
to be involved in plaque maturation and decreased stability of more advanced 
atherosclerotic lesions (Bobryshev, 2000d). This is likely related to the almost 
unparalleled ability of DC to secrete the proinflammatory cytokines that exacerbate 
atherosclerosis. Dendritic cell egress correlates with regression of the developing 
atheroma (Angeli et al., 2004c). oxPAPC likely impedes DC emigration by preventing 
their maturation into highly motile mature DC (Bluml et al., 2005a). Our studies suggest 
an additional effect of oxPAPC-activated DC in the progression of atherosclerosis: 
induction of the proatherogenic enzyme PAFAH.  
 
The THP1 monocytic cell line was used primarily as a model for DC in this study. DC 
were generated from primary cells which, despite the high concentrations of cytokines 
they are differentiated with, have the potential to respond differently from subject to 
subject. We observed that THP1 monocytes and DC respond similarly to oxPAPC, long-
chain fractions and to Butaprost (Figures 9, 10 and 11). However, THP1 monocytes are 
more sensitive to BW245C, the DP1 agonist than are DC (Figure 11). Additionally, while 
DC are highly sensitive to IL-6, generating 8-fold responses on a consistent basis, THP1 
monocytes respond more similarly to macrophages (Figures 12B and 12E). We are 
intrigued by this disparity in an otherwise excellent model for the DC. IL-6 Receptor is 
highly expressed at the cell surface of THP1 monocytes and in concentrations that dwarf 
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the DC. We postulate that this could be a consequence of increased IL-6R expression 
following the activation of DC by oxidized phospholipids. Alternatively, there could be 
an additional pathway following DP1 activation that is independent of IL-6. Further 
investigation is certainly warranted to determine the cause of these different responses.   
 
The role of PAFAH in cardiovascular disease is somewhat controversial.  Early studies 
suggested that PAFAH is a protective enzyme that limits the induction of atherosclerosis, 
likely because it catabolizes pro-atherogenic ox-LDLs and/or protects lipoproteins from 
oxidation (Noto et al., 2003a;Stafforini et al., 1997f;Stremler et al., 1989a;Watson et al., 
1997b).  For example, the incidence of myocardial infarction and atherosclerotic 
occlusive disease are elevated in Asian subjects with loss of function mutations in 
PAFAH (LIU et al., 2006;Yamada et al., 1998a;Yamada et al., 2000a).   In animal 
models, PAFAH promotes egress of DC from lesions, reduces neointima formation, and 
lessens severity of atherosclerosis (Arakawa et al., 2005a;Quarck et al., 2001c;Turunen et 
al., 2005a) (Angeli et al., 2004a).  In contrast, most recent studies suggest that PAFAH is 
at the very least a marker for vascular disease and may even be pro-atherogenic in 
Western populations (Blankenberg et al., 2003b).  A growing body of literature indicates 
associations between elevated plasma PAFAH and cardiovascular diseases such as 
coronary artery calcification, myocardial infarction and ischemic stroke (Ballantyne et 
al., 2004b;Ballantyne et al., 2005a;Blake et al., 2001a;Packard et al., 2000a) (Johnston et 
al., 2006a;Unno et al., 2000). Although plasma PAFAH necessarily correlates with LDL 
levels (Albert et al., 2005), most studies suggest PAFAH as an independent predictor for 
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cardiovascular events (Zalewski and Macphee, 2005b). The relative risk associated with 
elevated PAFAH is relatively modest, typically in the range of ~2.0. In Phase III clinical 
trials, a selective inhibitor of PAFAH (Darapladib) reduced plasma CRP and IL-6 and 
slowed progression of the necrotic core (Wilensky et al., 2008). Together, these data 
suggest that PAFAH has an active role in the progression of atherosclerosis, likely related 
to products of the PAFAH reaction that are proinflammatory and thereby exacerbate 
atherogenesis (Chen, 2004b;Tselepis and Chapman, 2002b). It is possible that the impact 
of PAFAH differs in early versus late stages of disease. Induction of PAFAH by mildly 
oxidized LDLs in early atheromas may be a protective response intended to limit 
accumulation of proatherogenic oxLDL. In more mature lesions, proinflammatory 
products of the PAFAH reaction may accumulate and exacerbate disease. Additional 
studies are necessary to test this hypothesis and more clearly delineate the role of PAFAH 
in pathogenesis of atherosclerosis. 
 
Data from our study and others have correlated oxPAPC with IL-6 signaling and Stat3 
activation as well as lesion development in vivo. Our data demonstrate a role for IL-6 in 
oxPL-stimulated PAFAH expression. However, there are likely additional consequences 
of oxPL-mediated induction of IL-6 within the atheroma. Elevated IL-6 is consistently 
measured in atherosclerotic plaques of humans, rabbits and mice and, like PAFAH is 
present particularly in the unstable shoulder region of the plaque (Ikeda et al., 
1992;Schieffer et al., 2000;Seino et al., 1994;Sukovich et al., 1998). IL-6 knockout mice 
have impaired monocyte recruitment and recombinant IL-6 exacerbates early 
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atherosclerosis in ApoE null mice (Huber et al., 1999;Romano et al., 1997). These data 
suggest a key role for IL-6 in atherosclerosis development and that long chain oxPL 
likely contribute to the pathogenesis of atherosclerosis by promoting IL-6 production by 
DC. They also prompt the hypothesis that in addition to its pro-atherogenic role, oxPL-
stimulated IL-6 may be involved in other diseases. Long-chain oxPL are generated as a 
result of oxidative stress associated with a variety of inflammatory diseases and many of 
these disorders are induced/ exacerbated by IL-6 (Gruber et al., 2007). Thus, we 
anticipate that future studies will show that oxPL-activated DC are associated with 
pathogenesis of atherosclerosis as well as further inflammatory diseases.  
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CHAPTER III: THE REGULATION OF PLATELET ACTIVATING FACTOR 
ACETYLHYDROLASE BY PLATELET ACTIVATING FACTOR  
 
3.1 INTRODUCTION  
 
Platelet activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a 
potent pro-inflammatory phospholipid. It is involved in a variety of inflammatory 
diseases including acute pancreatitis (Wilson et al., 1998), periodontitis (Emingil et al., 
2001;Garito et al., 1995), sepsis (Zimmerman et al., 2002) and atherosclerosis (Tselepsis 
and Chapman, 2002). PAF’s signaling abilities are diverse, inducing a wide range of 
inflammatory processes. First identified for its ability in the activation of platelets 
(Benveniste, 1974), PAF also induces the production of eicosanoids by macrophages and 
the adhesion of activated leukocytes to endothelial cells (Ding et al., 1992;Schaloske et 
al., 2005;Stewart et al., 1990). Many of the inflammatory actions of PAF are mediated 
through its G-protein coupled receptor (PAF-R) (Honda et al., 2002;Shimizu et al., 1992) 
which has been shown to couple to different G protein alpha subunits depending upon the 
cell type (Shimizu et al., 1992).  
 
PAF’s actions are terminated upon its enzymatic degradation into lyso-PAF and acetate. 
The enzyme responsible for the blunting of PAF’s effects is the monocyte-derived 
phospholipase A2, PAFAH. Like PAF, PAFAH is associated with inflammatory diseases 
including atherosclerosis and periodontitis (Al Darmaki et al., 2003;Rufail et al., 
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2005;Tselepis and Chapman, 2002a). Despite the consequence of this enzyme in 
hydrolyzing PAF and its relative contribution to the resolution of inflammation, its 
regulation is poorly understood. Lipopolysaccharide (LPS) induces PAFAH expression in 
decidual macrophages and increases PAFAH promoter activity in RAW264.7 
macrophages (Narahara et al., 1993;Wu et al., 2004). However, alternative studies have 
shown the suppression of PAFAH promoter activity by LPS in RAW264.7 macrophages 
(Cao et al., 1998d). We have demonstrated the induction of PAFAH by the inflammatory 
cytokine IL-6 in monocytes and DC and to a significantly lesser extent in macrophages 
(Figures 12 and 13). However, other investigators have indicated that the RAW264.7 
macrophage cell line is unresponsive to IL-6 (Cao et al., 1998d). PAF induces PAFAH 
transcriptional activity in human embryonic kidney (HEK) cells stably transfected with 
the PAF receptor (Cao et al., 1998d).  
 
PAF-like oxPL such as POVPC and PGPC are present in short-chain fractions of 
oxPAPC (Marathe et al., 1999). Importantly, the PAF receptor may mediate the signaling 
of PAF-like lipids. Endothelial cell activation by phospholipid oxidation products 
including POVPC, is inhibited by the PAF receptor antagonist WEB2086 
(Subbanagounder et al., 1999). Additionally, POVPC signals in part through the PAF 
receptor on human macrophages (Pegorier et al., 2005). Our data suggest that long-chain, 
but not short-chain fractions of oxPAPC induce PAFAH in monocytes and DC (Figure 
10). PGPC significantly induces PAFAH in DC but this is does not compare to the robust 
induction initiated by long-chain fractions of oxPAPC (Figure 10). While PAF induces 
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PAFAH in macrophages (Cao et al., 1998d), POVPC does not significantly alter PAFAH 
in DC (Figure 10) despite the expression of the PAF receptor in these cells. We were 
intrigued by the diverse responses to these stimuli by cells lines and models used to study 
PAFAH. We hypothesized that as bona fide PAF induces PAFAH in HEK cells, the same 
response would be observed in monocytes.  
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3.2 MATERIALS AND METHODS 
 
3.2.1 Materials:  
Buffy coat was purchased from Virginia Blood Services (Richmond, VA). THP-1 human 
monocytes were purchased from the American Type Culture Collection (Manassas, VA). 
[3H-]PAF was purchased from New England Nuclear/PerkinElmer (Boston, MA). 1-
alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) and lyso-PAF were purchased from 
Avanti Polar Lipids (Alabaster, AL). Lipopolysaccharide (LPS) and Fetal Calf Serum 
were purchased from Sigma (St Louis, MO). Human Serum was from Cambrex 
(Walkersville, MD). Lymphocyte separation medium was from MP Biomedicals (Solon, 
OH). RT-PCR primers were purchased from Integrated DNA Technology (Coralville, 
IA).  
 
3.2.2 THP-1 Monocyte Culture  
THP-1 human monocytes were maintained in RPMI with 10% Fetal Calf Serum with 
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. THP-1 monocytes 
were maintained between 2x105/ml and 1x106/ml, were fed approximately every two 
days and passaged at least once a week. Cells were passaged to 2x105/ml the day 
previous to treatment with viability at the onset of experiments typically greater than 
98%. Cells were maintained under standard cell culture conditions at 37°C and 5% CO2 
and were stimulated in serum-free media.  
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3.2.3 Primary Cell Culture and Differentiation  
Approximately 40ml of Buffy coat was diluted with 40ml RPMI. Diluted buffy coat was 
layered on a ficoll gradient then centrifuged for 30 minutes at 300g at 20°C. The fuzzy 
mononuclear layer was washed three times with RPMI and centrifugation at 1500g for 10 
minute washes. Each time the supernatant was removed and the pellet washed again. 
After three washes the pellet was resuspended in RPMI supplemented with 10% Human 
AB Serum. Cells were plated at a density of 107 per well in 6 well plates and incubated 
for 1-2 hours at standard cell culture conditions. Non-adherent cells were removed and 
monolayer was washed 3 times with plain RPMI. Monocytes were treated in serum-free 
media at this point. Other monocytes were induced to differentiate with cyokines for 7 
days into DC with 800U/ml GM-CSF and 500U/ml IL-4 in RPMI with 10% Fetal Calf 
Serum or into Macrophages with 1000U/ml M-CSF in RPMI with 10% Human Serum. 
Macrophage and Dendritic cell RPMI media was also supplemented with 2mM 
Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. 
 
3.2.4 Platelet Activating Factor Acetylhydrolase Activity Assays  
Substrate consisted of 50uM 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine with 0.05 µCi 
of hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine, 1-O-[acetyl-(N)-3H] 
(NEN/PerkinElmer; 13.5 Ci/mmol) added as a tracer. Substrate was incubated with 
conditioned medium (enzyme source) and incubated for 30 minutes at 37°C. PAFAH 
activity was determined as release of [3H] acetate as quantified by scintillation counting. 
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3.2.5 RNA Isolation and Platelet Activating Factor Acetylhydrolase Quantitative 
Real-Time PCR  
RNA was isolated with the Trizol reagent (Invitrogen). PAFAH specific primers were 
used to amplify product and normalized to 18S rRNA. PAFAH mRNA was measured by 
quantitative real time PCR (qPCR). PAFAH and 18S specific primers and Taqman 
probes were as follows; PAFAH probe 5’atgatcgccttgacaccctttgga-3’, sense 
5’tgcgtttatattatccatcccaa-3’ and antisense 5’agttgtcattgcaccaaagagt-3’. 18S probe 
5’cgagccgcctggataccgcagc-3’, sense 5’aaaattagagtgttcaaagcaggc-3’ and anti-sense 
5’cctcagttccgaaaaccaacaa-3’. Real time PCR reactions were performed with the 
TaqMan® One-Step kit from ABI on an ICycler instrument from BioRad. 
 
3.2.6 Statistical Analyses 
Data are presented as mean +/- standard deviation. Student t-tests were performed and 
statistical significance is expressed as *p<0.05, **p<0.01, ***p<0.001.
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PAFAH  Sense 5’tgcgtttatattatccatcccaa-3’  
 Anti-
Sense 
5’agttgtcattgcaccaaagagt-3’  
 Probe 5’atgatcgccttgacaccctttgga-
3’ 
 
18S Sense 5’aaaattagagtgttcaaagcaggc-3’ 
 
 Anti-
Sense 
5’cctcagttccgaaaaccaacaa-
3’ 
 
 Probe 5’cgagccgcctggataccgcagc-
3’ 
 
 
Table 5: Quantitative Real Time PCR Primers and Probe Sequences 
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3.2 RESULTS  
 
3.2.1 Platelet Activating Factor Suppresses PAFAH in Dendritic Cells 
 
Monocytes, macrophages and dendritic cells are the primary source of PAFAH in vivo. 
Therefore, monocytic cells were used as a model by which to study the regulation of 
PAFAH by PAF. Monocytes express low levels of PAFAH however their differentiation 
into DC or MO is accompanied by a robust increase in PAFAH expression (Elstad et al., 
1989). Therefore, DC and MO were used as model cells with which to investigate the 
regulation of PAFAH by PAF. Differentiated DC and MO were stimulated with PAF for 
16 hours before PAFAH was quantified by qPCR or by radiometric activity assay. 
PAFAH expression was suppressed by approximately 50 percent in dendritic cells treated 
with 100nM PAF (Figure 16 A-B). This decline in PAFAH expression was accompanied 
by a similarly reduced level of activity in PAF-treated monocytes (Figure 16B). 
Surprisingly, macrophage PAFAH was unaffected by PAF stimulation at both the 
expression and activity levels (Figure 16A and B).  
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Figure 16: PAF Suppresses PAFAH Expression in DC. Macrophages and Dendritic 
cells were stimulated with 100nM PAF for 16 hours. A. PAFAH expression was 
quantified from cell fraction or B. PAFAH activity was quantified in cell free 
supernatants. Results are expressed relative to vehicle control and are shown as mean ± 
st.dev. **p<0.01.  
A B
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3.2.2 c-PAF Suppresses PAFAH Expression in Monocytes, DC and Macrophages 
 
In vivo, PAF is known to be rapidly hydrolyzed by PAFAH. To test the effects of PAF 
upon PAFAH expression independent of the effects of PAFAH activity, cells were 
treated with methyl carbamyl-PAF (c-PAF), a non-hydrolyzable analog of PAF. PAFAH 
expression and activity were significantly suppressed in DC (Figure 17A-B). 
Macrophages treated with c-PAF showed a trend towards lower PAFAH expression 
compared to vehicle treated cells, however this did not reach statistical significance 
(p=0.394). In contrast to PAF, non-hydrolyzable c-PAF did however significantly 
suppress macrophage PAFAH activity by approximately 60 percent (Figure 17B). To 
further investigate the regulation of PAFAH by PAF upon cells of the monocytic-lineage, 
THP1 monocytes were incubated with c-PAF. We observed a similarly dramatic 
suppression of PAFAH in the monocyte cell line (Figure 17C).  
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Figure 17: c-PAF Suppresses PAFAH Expression in Monocytes, DC and 
Macrophages. Macrophages, Dendritic cells and THP1 monocytes were stimulated with 
100nM cPAF for 16 hours. A. PAFAH expression was quantified from RNA isolated 
from the cell fraction of macrophages or dendritic cells B. PAFAH activity was 
quantified in cell free supernatants of macrophages or dendritic cells. C. PAFAH 
expression was measured in THP1 monocytes. Results are expressed relative to vehicle 
control and are shown as mean ± st.dev. **p<0.01, ***p<0.001. 
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3.2.3 c-PAF Suppresses PAFAH Promoter Activity in Monocytes 
 
Stafforini’s group demonstrated that PAF induces PAFAH transcriptional activity in 
HEK cells stably transfected with PAF receptor cDNA (Cao et al., 1998d). However, our 
data show that PAF suppresses PAFAH expression in DC (Figure 17) and that the PAF 
analog c-PAF suppresses PAFAH expression in MO, DC and THP1 monocytic cell line 
(Figure 17). To determine whether these effects upon transcriptional activity are cell-type 
specific, we obtained the PAFAH-luciferase promoter construct from the Stafforini group 
and transfected it into THP1 human monocytes. Transfected THP1 monocytes were 
treated with c-PAF and PAFAH transcriptional activity was quantified using a luciferase 
activity assay. In contrast to effects reported by the Stafforini group in HEK cells, 
PAFAH promoter activity was significantly reduced by c-PAF by approximately 50 
percent (Figure 18). These data confirmed our observations regarding the suppressive 
effects of PAF and c-PAF and demonstrated that this regulation was at transcriptional 
level. 
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Figure 18: c-PAF Suppresses PAFAH Promoter Activity in Monocytes. THP1 
monocytes transiently transfected with a PAFAH reporter construct were treated with c-
PAF for 16 hours. PAFAH promoter activity was measured in cell lysates and normalized 
to B-galactosidase. Mean ± st.dev of three independent experiments is shown. 
***p<0.001. 
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3.2.4 Basal PAFAH Activity is Low in Dendritic Cells 
 
We were intrigued by the differential responses of macrophages and dendritic cells to 
PAF and c-PAF. PAF suppressed PAFAH activity in DC alone, c-PAF significantly 
suppressed PAFAH activity in both DC and macrophages (Figures 16-17). While c-PAF 
is a non-hydrolyzable analog of PAF, PAF itself is catabolyzed by PAFAH. Previous 
studies by our laboratory demonstrated that basal PAFAH is high in macrophages 
compared to DC (Al Darmaki et al., 2003). We hypothesized that high levels of PAFAH 
activity present in macrophages rapidly hydrolyze PAF. As c-PAF is a non-hydrolyzable 
analog, the levels of PAFAH activity present would not affect signaling induced by c-
PAF. To confirm that our macrophages have similarly high levels of PAFAH to those 
previously shown, we quantified basal PAFAH activity and mRNA in macrophages and 
DC. Consistent with observations by Al Darmaki et al, we found that macrophages have 
approximately 5-fold greater resting levels of PAFAH expression and activity compared 
to DC (Figure 19) (Al Darmaki et al., 2003). This suggests that high levels of basal 
PAFAH in macrophages might limit the response to PAF.  
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Figure 19: Basal PAFAH Is Low in Dendritic Cells. Macrophages and dendritic cells 
were incubated overnight in the absence of serum then PAFAH quantified. A. PAFAH 
expression was analyzed using qPCR. B. PAFAH activity was measured using 
radiometric assay. Data are representative of at least five independent experiments and 
are displayed as mean ± st.dev. ***p<0.001. 
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3.2.5 POVPC Suppresses PAFAH Expression in THP-1 Monocytes 
 
Short-chain PAF-like oxidized phospholipids have been identified in preparations of 
mildly oxidized LDL (Marathe et al., 2001). POVPC, in particular has been shown to 
partially signal through the PAF receptor (Pegorier et al., 2005). DC treated with POVPC 
show no alteration in PAFAH (Figure 10B). However, while DC possess lower PAFAH 
expression than macrophages, they have significantly higher levels than monocytes. 
POVPC is a potential target for PAFAH suggesting that DC express ample PAFAH to 
hydrolyze POVPC thereby preventing signaling. THP1 monocytes express low levels of 
PAFAH. This led to the hypothesis that like PAF, POVPC would suppress PAFAH 
expression in THP1 monocytes. To test this hypothesis we treated THP1 monocytes with 
POVPC and quantified PAFAH expression by qPCR. The exceptionally low levels of 
PAFAH activity present in THP1 monocytes did not allow the quantification of 
enzymatic activity. POVPC dose-dependently suppresses PAFAH with approximately 
ninety percent suppression at 50µM (Figure 20). The data in Figure 20 represents a single 
experiment. Reproducibility proved difficult when stimulating THP1 monocytes with 
POVPC. Perhaps because the basal expression of PAFAH in these cells is close to the 
lower limit of detection. In some experiments THP1 monocytes were sensitive to POVPC 
and underwent cell death. Our data suggest that POVPC may suppress PAFAH 
expression but further experimentation must be conducted for conclusive evidence.
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Figure 20: POVPC Suppresses PAFAH Expression in THP1 Monocytes. THP1 
monocytes were stimulated with 0, 5, 10, 25 or 50µM POVPC for 16 hours. PAFAH 
expression is normalized to 18S expression. Results are from a single experiment 
conducted in triplicate. Mean ± StDev are shown. ** p<0.01. 
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3.2.6 PAFAH Expression is Altered by Lyso-PAF 
 
PAFAH hydrolysis of PAF leads to the formation of lyso-PAF and acetate. To determine 
whether the products of PAFAH action have any effects upon expression of the enzyme, 
we treated DC and macrophages with lyso-PAF. In a single experiment, dendritic cells 
and macrophages treated with 100nM lyso-PAF responded in a differential manner. 
Lyso-PAF induced PAFAH expression significantly in macrophages but not DC (Figure 
21). These data are from a single experiment. Upon a second occasion, these observations 
were not repeated, and no change in PAFAH expression was observed (data not shown). 
Further investigation is warranted to determine the effects of lyso-PAF upon PAFAH 
expression.  
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Figure 21: PAFAH Expression is Altered by Lyso-PAF. Macrophages and Dendritic 
cells were treated with 100nM lyso-PAF for 16 hours. PAFAH expression was quantified 
by qPCR. Data shown represent a single experiment where the relative level of PAFAH 
expression is shown relative to vehicle control. *p<0.05. 
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3.4 Discussion 
 
PAF and the enzyme that inactivates it, PAFAH, are linked to a variety of inflammatory 
diseases (Zimmerman et al., 2002). Several researchers have investigated the regulation 
of PAFAH but there is a general lack of consistency in results that may be a direct 
consequence of the models used. Our study focused upon the use of the physiologically 
relevant monocytic cell model. We demonstrate that PAF suppresses PAFAH expression 
and this is reflected in an associated decrease in enzyme activity (Figure 16). PAFAH 
expression increases dramatically as monocytes differentiate (Elstad et al., 1989) and 
furthermore PAFAH expression is significantly higher in macrophages versus DC (Al 
Darmaki et al., 2003). High levels of PAFAH activity would result in more rapid 
catabolism of its substrates. The hydrolysis of PAF in macrophages likely plays an 
important role in the blunting of the suppressive signaling. Use of the non-hydrolyzable 
compound c-PAF allowed us to effectively inhibit PAFAH by making the relative 
PAFAH activity redundant. C-PAF suppressed macrophage PAFAH expression in a 
manner comparable to DC and THP1 monocytes (Figure 17). This suggests that the basal 
level of PAFAH activity possessed by the cell limits the overall effect of PAF upon 
PAFAH expression. Our study is the first to demonstrate the regulation of PAFAH by 
PAF in a physiologically relevant cell model. This may have important consequences for 
our understanding of the regulation of PAFAH in inflammatory conditions.  
 
Al-Darmaki et al, showed that PAF accumulation is higher in DC than in macrophages 
(Al Darmaki et al., 2003). The same group also demonstrated that PAF-induced PGE2 
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release is higher in DC than in macrophages and that this is likely a direct consequence of 
low DC PAFAH activity and consequent longer half-life of PAF in DC (Al Darmaki et 
al., 2003). Our study reveals an additional consequence of the relative level of PAFAH 
activity. In cells with low basal PAFAH, PAF is able to lower PAFAH expression further 
which may allow inflammation to persist. For example, patients with neonatal necrotizing 
enterocolitis (NE) have elevated PAF levels while plasma PAFAH is decreased (Hsueh et 
al., 2003). Additionally, a similar pattern of significantly higher plasma PAF and lower 
PAFAH activity is measured in subjects with Hepatitis C Virus (HCV) (Caini et al., 
2007). Our data suggests that the induction of PAF is responsible for significantly lower 
PAFAH expression and activity in patients with NE and HCV. In HEK cells, PAF 
induced PAFAH transcription (Cao et al., 1998d) suggesting a negative feedback loop for 
the inactivation of PAF. Our study reveals that in the physiologically relevant model of 
monocytes and monocyte-derived cells, PAF suppresses PAFAH. This in vitro 
phenomenon is supported by the observations in human inflammatory diseases such as 
NE and HCV. This suggests that the continued formation of PAF leads to a prolonged 
suppression of PAFAH. This allows the persistence of PAF and hence chronic 
inflammation ensues.  
 
The recruitment of immature DC to inflammatory sites is a critical component of the 
inflammatory response. Many factors have been shown to induce this recruitment 
including PAF, chemokines and sphingosine 1-phosphate (S1P) (Dichmann et al., 
2000;Idzko et al., 2002;Sozzani et al., 2000). The PAF receptor is present in immature 
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DC however its expression is lost upon their maturation (Dichmann et al., 2000) 
reinforcing the role of PAF in the immature DC. During maturation DC acquire the 
ability to migrate to secondary lymphoid tissues where they prime T-cells. PAF is not 
required for the migration of mature DC as evidenced by the loss of PAF receptor 
expression (Dichmann et al., 2000). We propose that PAF-mediated suppression of 
PAFAH is required to maintain elevated levels of PAF for the continued influx of 
immature DC to the site of inflammation and therefore the progression of the 
inflammatory response.  
 
PAF is not the sole bioactive phospholipid that has been suggested to signal through the 
PAF-R. During atherosclerosis, short-chain oxidized and fragmented phospholipids are 
generated upon the oxLDL particles that have also been proposed to bind the PAF-
receptor (Pegorier et al., 2005). Marathe et al showed oxLDL to contain PAF-like lipids 
(Marathe et al., 2001). oxLDL stimulates activation of the PAF-R in monocytes and 
down-regulation of LPS-induced PAF-R expression in monocyte-derived macrophages 
(Beaudeux et al., 2004a;Hourton et al., 2001). Lehr et al showed administration of 
oxLDL in vivo, promoted leukocyte adhesion to endothelium and this was inhibited by 
the PAF-R antagonist WEB2170 (Lehr et al., 1993a). If such short-chain PAF-like lipids 
are capable of signaling through the PAF-receptor, it is likely that they will then also 
suppress PAFAH expression in DC. Our preliminary data (Figure 10B) suggest that DC 
do not respond to 10uM POVPC and a modest induction of PAFAH is observed in 
response to PGPC. In THP1 monocytes, early experiments showed that POVPC could 
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dose-dependently suppress PAFAH expression (Figure 20) however additional 
experiments revealed that even moderate doses of POVPC, but not PGPC potently kills 
cells. We are intrigued by the sensitivity of monocytes to POVPC and further studies will 
investigate whether lower doses modulate PAFAH expression.  
 
In summary, we have demonstrated that PAF suppresses PAFAH expression. The relative 
level of PAFAH activity present in the cell affects this. We also show that the PAF-like 
oxPL, POVPC may also suppress PAFAH expression although further investigation is 
warranted to confirm our preliminary results. The suppression of PAFAH may have 
important implications for the development of the immune response and atherosclerosis.  
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CHAPTER IV: THE REGULATION OF PLATELET ACTIVATING FACTOR 
ACETYLHYDROLASE IN PERIODONTITIS  
 
 
4.1 INTRODUCTION 
 
Periodontitis is an inflammatory disease of the oral cavity that is bacterial in origin 
(Grossi et al., 1994;Grossi et al., 1995). Gram-negative bacteria such as Actinobacillus 
actinomycetemcomitans and Porphyromonas gingivalis infiltrate the gingival tissue to 
initiate an inflammatory response that is the main destructive component of the disease. 
Periodontitis may be classified by the age of onset as well as by the affected areas. 
Aggressive forms of the disease usually develop in young adults and cause significant 
bone destruction and attachment loss. Localized aggressive periodontitis (LAgP) affects 
usually only first molars and incisors and Generalized Aggressive periodontitis (GAgP) 
has a widespread pattern specifically affecting a larger number of teeth (Gustke, 
1998a;Gustke, 1998b). These aggressive forms of periodontitis are rare and their 
occurrence is influenced heavily by genetics and race. Adult onset periodontitis is known 
as chronic periodontitis and generally begins beyond age 35. The disease is characterized 
by progressive loss of alveolar bone and soft tissue but is not as aggressive as the early 
onset forms.  
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Accumulating evidence suggests an elevated risk of cardiovascular disease development 
in periodontitis patients. These diseases share common risk factors such as age, diabetes 
mellitus, obesity, smoking and infection (Pischon et al., 2007;Schenkein et al., 1995). 
Largely, the evidence points toward chronic periodontitis patients as being at risk of 
developing CVD. However, there are also data suggesting that AgP subjects may be at 
risk for CVD. For example, GAgP subjects have elevated pro-atherogenic small dense 
LDL in their plasma (Rufail et al., 2005). Schenkein, Tew and others have shown that 
AgP patients, like CP subjects have elevated anti-cardiolipin protein compared to non-
periodontitis (NP) subjects (Schenkein et al., 2003a;Schenkein et al., 2007) (Salzberg et 
al., 2006). Patients with periodontal disease also have higher concentrations of IgG anti-
PC and anti-CL that is cross reactive with oral bacterial antigens and human antigens 
including oxLDL (Schenkein et al., 1999). The gingival crevicular fluid of periodontitis 
patients also contains anti-PC and anti-oxLDL (Schenkein et al., 2004). Infection with 
P.gingivalis has been demonstrated to exacerbate atherosclerosis in ApoE-deficient mice 
(Lalla et al., 2003). While Grau et al have shown that periodontal disease is a risk factor 
for ischemic stroke (Grau et al., 2004b). Odds ratios for periodontitis and atherosclerosis 
vary from 0.79 to 2.68. Clinical treatment of periodontitis significantly reduces PAF 
levels in the crevicular fluid and improves periodontitis suggesting that PAF is an 
important inflammatory mediator in this disease (Rasch et al., 1995). Altogether these 
data are suggestive that AgP is connected to atherosclerosis. Further studies are 
warranted to investigate the full extent of the relationship between these two diseases.   
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Monocytes from subjects with LAgP have a greater tendency to differentiate into DC 
than their NP counterparts (Barbour et al., 2002c). Our data demonstrate that DC are 
hyperresponsive to long-chain oxPL and PAF, compared to macrophages. These facts led 
us to hypothesize that AgP monocytes are hyperresponsive to oxPL and PAF owing to 
their propensity to differentiate into DC, and this may have consequences in 
atherosclerosis. Given the strong association of PAFAH in atherosclerosis any alteration 
in the expression of this enzyme could have an adverse outcome on the progression of the 
disease. Therefore we investigated the regulation of PAFAH by oxPL and PAF in 
periodontitis. 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Materials  
OxPAPC and its fractions were prepared as described previously (Birukov et al., 2004c)). 
M-CSF, GM-CSF and IL-4 were all from RnD Systems (Minneapolis, MN). [3H-]PAF 
was purchased from New England Nuclear/PerkinElmer (Boston, MA). 1-alkyl-2-acetyl-
sn-glycero-3-phosphocholine (PAF) and 1-palmitoyl-2-arachidonyl-sn-glycero-3-
phosphocholine were purchased from Avanti Polar Lipids (Alabaster, AL). 
Lipopolysaccharide (LPS) and Fetal Calf Serum were purchased from Sigma (St Louis, 
MO). Human Serum was from Cambrex (Walkersville, MD). Lymphocyte separation 
medium was from MP Biomedicals (Solon, OH). RT-PCR primers were purchased from 
Integrated DNA Technology (Coralville, IA).  
 
4.2.2 Human Subjects 
Subjects were recruited, and periodontal health was assessed by the Clinical Research 
Center for Periodontal Diseases (CRCPD), Virginia Commonwealth University. 
Individuals studied were non-smoking males and females. Clinical classification of 
disease is outlines in Table 6.  
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Periodontal Status Guidelines 
Non-Periodontitis (NP) No evidence of attachment loss at more than one site, or 
pockets greater than 3mm. Gingival inflammation may be 
present. Age- and race-matched with periodontitis 
subjects 
Localized Aggressive 
Periodontitis (LAgP) 
At least 4 mm attachment loss (AL) on at least 2 
permanent first molars and incisors (at least one molar 
must be affected) and no more than 2 teeth, which are not 
first molars or incisors, affected by 5 mm AL or more. 
Subjects have evidence of disease onset from puberty to 
age 35 and of rapidly progressive loss of attachment 
Generalized Aggressive 
Periodontitis (GAgP) 
At least 8 teeth affected (5mm AL or more), at least 3 of 
which are not first molars and incisors. Subjects have 
evidence of disease onset from puberty to age 35 and of 
rapidly progressive loss of attachment 
 
Table 6: Guidelines of Periodontal Status Applied to Subjects Within this Study 
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4.2.3 Primary Cell Culture and Differentiation  
Approximately 40ml of Buffy coat was diluted with 40ml RPMI. Diluted buffy coat was 
layered on a ficoll gradient then centrifuged for 30 minutes at 300g at 20C. The 
mononuclear layer was washed three times with RPMI and centrifugation at 1500g for 10 
minute washes. Each time the supernatant was removed and the pellet washed again. 
After three washes the pellet was resuspended in RPMI supplemented with 10% Human 
AB Serum. Cells were plated at a density of 107 per well in 6 well plates and incubated 
for 1-2 hours at standard cell culture conditions. Supernatant and non-adherent cells were 
removed and monolayer was washed 3 times with plain RPMI. Monocytes were treated 
in serum-free media at this point. Other monocytes were induced to differentiate with 
cytokine for 7 days into DC with 800U/ml GM-CSF and 500U/ml IL-4 in RPMI with 
10% Fetal Calf Serum or into Macrophages with 1000U/ml M-CSF in RPMI with 10% 
Human Serum. Macrophage and Dendritic cell RPMI media was also supplemented with 
2mM Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. FACS analysis was 
previously used to confirm that differentiation conditions were successful (Al Darmaki et 
al., 2003).  
 
4.2.4 Isolation of Low-Density Lipoprotein  
Human peripheral blood was drawn after an overnight fast and collected in five, 10ml BD 
vacutainers with K3 EDTA. Blood was divided equally into two centrifuge tubes and 
centrifuged at 3,000g for 20min at 4°C. Plasma was collected after this first 
centrifugation and was supplemented with 500ul Protease I inhibitor NaN3 (0.02%) and 
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EDTA (1mM). Plasma was mixed with stock density solution then transferred to two 
centrifuge tubes. An overlay of stock density solution was added to the tube. Samples 
were centrifuged at 45,000rpm at 20°C for 20 hours. After the first centrifugation, the 
upper cloudy layer of VLDL was removed. The infranatant density was checked using a 
refractometer to ensure it was between 1.015 and 1.017. Once this certain, the remaining 
infranatant was removed and the pellet resuspended. Stock density solution was added 
and the overlay added over the top. Samples were centrifuged for a further 45,000rpm at 
20°C for another 20 hours. At the end of this time, the upper cloudy layer of LDL was 
removed from the tubes. Density of infranatant was checked as 1.063 then LDL stored 
under argon/nitrogen at 4°C until use.  
 
4.2.5 Protein Assay of Low Density Lipoprotein  
Protein concentration was determined using a modified Lowry method with a BSA 
standard (Miwa et al., 1988). Reagent A was made with 20ml CTC reagent, 40ml 5% 
SDS solution and 20ml 0.8M NaOH. Reagent B was Folin Reagent diluted 1:6 with H20. 
Dialyzed LDL or BSA were incubated with 0.5ml Reagent A for 10 minutes at room 
temperature. Then 0.25ml Reagent B was added, mixed and incubated at room 
temperature for 30 minutes. At this point absorbance was measured in a 
spectrophotometer at 750nm against blank.  
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4.2.6 Oxidation of Low Density Lipoprotein  
LDL was dialyzed before oxidation or before incubation with cell cultures using dialysis 
membrane in phosphate buffered saline. Stir bar present over night in cold room. LDL 
Oxidation LDL was preserved in its native form (nLDL) or oxidized by 2.5μM CuS04 as 
described previously (Anthonsen et al., 2000a) to produce oxidized LDL (oxLDL). LDL 
preparations were supplemented with NaN3 and EDTA post-oxidation to preserve and 
protect against further modification. Conjugated dienes were determined by 
spectrophotometric analysis of 50µg/ml LDL preparations at 234nm (nLDL<0.2, 
oxLDL=0.4). LDL was extensively dialyzed against PBS before incubating with cells. 
Cell cultures were treated with 50μg/ml LDL for 16 hours. 
 
4.2.7 Platelet Activating Factor Acetylhydrolase Activity Assays: Substrate consisted 
of 50µM 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine with 0.05 µCi of hexadecyl-2-
acetyl-sn-glyceryl-3-phosphocholine, 1-O-[acetyl-(N)-3H] (NEN/PerkinElmer; 13.5 
Ci/mmol) added as a tracer. Substrate was incubated with conditioned medium (enzyme 
source) and incubated for 30 minutes at 37°C. PAFAH activity was determined as release 
of [3H] acetate as quantified by scintillation counting. 
 
4.2.8 RNA Isolation and Platelet Activating Factor Acetylhydrolase Quantitative 
Real-Time PCR  
RNA was isolated with the Trizol reagent (Invitrogen). PAFAH specific primers were 
used to amplify product and normalized to 18S RNA (Table 7). PAFAH and 18S mRNA 
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was measured by quantitative real time PCR (qPCR). Primer and Probe Sequences are 
shown in Table 6. Real time PCR reactions were performed with the TaqMan® One-Step 
kit from ABI on an ICycler instrument from BioRad. 
 
4.2.9 Statistical Analyses  
Data are presented as mean +/- standard deviation. Student t-tests, ANOVA or Mann-
Whitney non-parametric analyses were performed and statistical significance is expressed 
as *P<0.05, **P<0.01, ***P<0.001. 
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PAFAH  Sense 5’tgcgtttatattatccatcccaa-3’  
 Anti-
Sense 
5’agttgtcattgcaccaaagagt-3’  
 Probe 5’atgatcgccttgacaccctttgga-
3’ 
 
18S Sense 5’aaaattagagtgttcaaagcaggc-3’ 
 
 Anti-
Sense 
5’cctcagttccgaaaaccaacaa-
3’ 
 
 Probe 5’cgagccgcctggataccgcagc-
3’ 
 
 
 
Table 7: PAFAH and 18S Primer and Probe Sequences
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4.3 RESULTS  
 
4.3.1 Aggressive Periodontitis Monocytes Spontaneously Differentiate Into DC 
 
Of the two aggressive forms of periodontitis, GAgP is the more severe. LAgP subjects’ 
monocytes have a propensity to differentiate into DC (Barbour et al., 2002b). We 
hypothesized that GAgP monocytes would also differentiate towards a DC phenotype 
rather than the predominantly macrophage population observed with non-periodontitis 
(NP) monocytes. To test this, monocytes isolated from NP and GAgP monocytes were 
allowed to spontaneously differentiate for seven days before morphology was observed. 
As shown in Figure 22, GAgP monocytes displayed a typically DC phenotype compared 
to NP monocytes. In this study we did not further investigate the phenotype or function of 
DC-like cells. These experiments will be conducted in the future to confirm that GAgP 
monocytes spontaneously differentiate into DC. However, the morphology of these cells 
suggests GAgP monocytes do indeed become DC, as previous studies have shown is the 
case with LAgP monocytes (Barbour et al., 2002a)   
    124
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Generalized Aggressive Periodontitis Monocytes Spontaneously 
Differentiate Into DC. Adherent monocytes isolated from NP or GAgP patients were 
cultured for 7 days in human serum. Photomicrographs of the cultures were taken and 
morphology studied. Arrows indicate the presence of cells with dendritic cell-like 
morphology. The results of a representative experiment are shown (n=3).
Non-Periodontitis Monocytes                   Generalized Aggressive Periodontitis Monocytes
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4.3.2 Basal PAFAH Is Low in Monocytes from Generalized Aggressive Periodontitis 
Subjects 
 
Maturation of monocytes into DC and macrophages is associated with a significant 
increase in PAFAH expression (Al Darmaki et al., 2003;Elstad et al., 1989). 
Macrophages especially have high levels of PAFAH that are 5-fold or greater than DC 
(Figure 19). Similarly, differentiated NP monocytes have significantly elevated levels of 
PAFAH compared to LAgP monocytes (Barbour et al., 2002c). We theorized that GAgP 
monocytes that are more likely to differentiate into DC have similarly low levels of basal 
PAFAH. To test this, relative PAFAH expression was quantified by qPCR (Figure 23). 
ANOVA statistical analyses revealed a probability value of p=0.009 between the groups. 
(F= 6.516) indicating that there is a low probability that these differences exist by random 
occurrence. Enzymatic activity assays confirmed that GAgP monocytes have 
significantly lower levels of PAFAH than NP monocytes (Figure 23B). We therefore 
conclude that GAgP monocytes have significantly lower basal PAFAH expression than 
NP monocytes.  
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Figure 2: Basal PAFAH Is Low in Periodontitis Monocytes 
NP=11; GAgP=8, LAgP=3 
 
 
 
Figure 23: Basal PAFAH Expression and Activity are Low in AgP Monocytes 
Macrophages and dendritic cells were incubated overnight in the absence of serum then 
PAFAH quantified. A. PAFAH expression was analyzed using qPCR. B. PAFAH activity 
was measured using radiometric assay. Data are representative of at least five 
independent experiments and are displayed as mean ± st.dev. *p<0.05. 
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4.3.3 PAF Suppresses PAFAH in GAgP but Not NP Monocytes 
 
We have demonstrated that PAF suppresses PAFAH expression in DC but not 
macrophages (Figure 16). GAgP monocytes look like DC and express low levels of basal 
PAFAH like DC. To determine whether these cells also respond in a manner analogous to 
that of DC, cells were treated with 100nM PAF for 16 hours. While NP monocytes did 
not respond to PAF, the levels of PAFAH in GAgP monocytes were significantly reduced 
by approximately 50% (Figure 24). Treatment of GAgP monocytes with the non-
hydrolyzable PAF analog c-PAF similarly reduced PAFAH expression (Figure 24). 
PAFAH was significantly suppressed in NP monocytes treated with c-PAF (Figure 24).  
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Figure 24: PAF Suppresses PAFAH Expression in GAgP Monocytes. Differentiated 
NP and GAgP monocytes were treated for 16 hours with 100nM PAF or c-PAF. PAFAH 
expression was quantified and normalized to 18S. Data are expressed as relative to 
vehicle control. NP are shown as open bars while GAgP monocytes are represented by 
grey bars. Data shown are from six independent patients that were age- and race-
matched. Mean ± st.dev. are shown. 
 
NP
GAgP
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4.3.4 Oxidized LDL Induces PAFAH in AgP Monocytes 
 
OxLDL is proatherogenic, signaling many events that lead to atherosclerosis 
development (Frostegard et al., 1990). Oxidized phospholipids in oxLDL are proposed to 
be targets for PAFAH (Foulks et al., 2009;Marathe et al., 2002). AgP monocytes 
differentiate into DC and possess low levels of PAFAH (Figures 22 and 23). 
Additionally, AgP monocytes respond to PAF and c-PAF in a manner analogous to that 
of DC (Figure 24). We hypothesized that AgP monocytes would respond to oxLDL like 
DC and PAFAH expression would be induced. To test this NP and AgP monocytes were 
stimulated with a mildly oxidized LDL species that is known to induce PAFAH 
expression in DC (Figure 14). Cells were treated overnight before PAFAH expression 
was analyzed by qPCR. NP monocytes were unresponsive to oxLDL with a mean fold 
induction of 0.86 in 11 samples. AgP monocytes, like DC were responsive to oxLDL 
with a mean induction of 3.34-fold (n=15). Statistical analyses revealed that the oxLDL-
mediated induction of PAFAH is significantly higher in AgP monocytes (p=0.0006). 
LAgP (n=4) and GAgP monocytes (n=11) were grouped together in this study. We 
observed that LAgP monocytes were particularly sensitive to oxLDL although additional 
subjects are required to fully investigate any differences between the GAgP and LAgP 
groups.   
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Figure 25: oxLDL Induces PAFAH in AgP Monocytes. Differentiated NP, and AgP 
monocytes were treated with 50µg/ml Mildly Oxidized LDL for 16 hours. PAFAH 
expression was quantified, normalized to 18S and is expressed as relative to vehicle 
control for each subject. Datapoints represent fold PAFAH induction for individual 
subjects in each group. NP subjects n= 11; AgP subjects n=15. 
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4.3.5 Oxidized Phospholipids Induce PAFAH Expression in GAgP Monocytes 
 
DC play an important role in inflammation and are emerging as key components in the 
development of the atherosclerotic plaque (Bobryshev, 2000e;Bobryshev, 2005). 
Oxidized Phospholipids are produced during atherosclerosis and mediate a variety of pro-
atherogenic events (Leitinger, 2003). These are significant bioactive components of 
oxLDL and we have shown that DC, but not MO are sensitive to oxPAPC, responding 
with a robust induction in the expression of PAFAH (Figure 9). Preliminary data with a 
relatively small number of subjects (n=1 NP; n=3 GAgP) indicates that GAgP monocytes 
that spontaneously differentiate into DC are also responsive to oxPAPC. With monocytes 
isolated from three subjects, oxPAPC stimulated PAFAH between two- and twelve-fold. 
Our preliminary observations suggest that the predominantly macrophage-like NP 
monocytes are unresponsive to oxPAPC. However, thus far monocytes from a single 
patient were stimulated with 50µg/ml oxPAPC. Additional NP and GAgP subjects will be 
analyzed to confirm these preliminary results.   
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4.4 DISCUSSION 
 
Our data show that like LAgP monocytes, GAgP monocytes express basal PAFAH at low 
levels (Al Darmaki et al., 2003) (Figure 23). This may have important consequences for 
inflammation in the context of the periodontal health of these subjects. Specifically, low 
PAFAH activity allows the persistence of pro-inflammatory PAF thus permitting chronic 
inflammation to ensue. GAgP is a particularly chronic type of aggressive periodontitis 
with attachment loss widespread through the oral cavity. PAF is known to accumulate in 
the gingival crevicular fluid of GAgP subjects and removal of this lipid eases symptoms 
of the disease (Rasch et al., 1995). We show that PAF suppresses PAFAH expression in 
GAgP monocytes (Figure 24). This suggests that an accumulation of PAF in AgP 
subjects would reinforce the inflammatory response by suppressing PAFAH. The non-
hydrolyzable PAF analog c-PAF reduces PAFAH expression in both NP and GAgP 
monocytes. This suggests that NP subjects that possess high PAFAH activity are well-
equipped to catabolyze pro-inflammatory PAF. However, GAgP subjects have a greater 
propensity to differentiate into DC with low PAFAH and PAF signaling persists. That is 
not to say that this is the sole factor in the persistence of PAF and for the disease itself. 
There are many factors at play including a genetic predisposition but the relative 
contribution of PAF, PAFAH and the DC is certainly a factor in this disease.  
 
In addition to the disadvantages of low or suppressed PAFAH expression in periodontitis, 
there may be important implications in atherosclerosis. PAF and oxPL contained upon 
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the oxLDL particle are involved in the pathogenesis of atherosclerosis (Marathe et al., 
2002). Pro-inflammatory oxLDL and oxPAPC potently stimulate PAFAH expression and 
activity in GAgP monocytes (Figures 25 and data not shown) but not NP monocytes. 
These observations are comparable to our observations in DC and macrophages (Figures 
9 and 14). Our research indicates that long-chain, but not short-chain oxPL are 
responsible for the induction of PAFAH in DC (Figure 10). It is therefore plausible that 
the same components of oxPAPC and oxLDL induce PAFAH expression in DC-like AgP 
monocytes. The role of PAFAH in atherosclerosis has been controversial although 
overwhelming data now suggest this enzyme is pro-atherogenic (Packard et al., 
2000b;Yamada et al., 2000b;Zalewski and Macphee, 2005a). GAgP monocyte 
differentiation is skewed towards a DC phenotype and these cells are sensitive to pro-
atherogenic stimuli (PAF and oxPAPC). The accumulation of DC in the atheroma 
combined with their PAFAH- and inflammatory cytokine-producing potential suggests a 
potential source of the susceptibility of periodontitis patients to atherosclerosis. To date 
the major epidemiological studies regarding periodontitis and atherosclerosis show 
modest odds ratios from 0.79 to 2.68. Moreover, these studies were conducted using 
subjects with chronic periodontitis and not those with AgP. Future studies by our group 
will focus upon the responses of CP monocytes to PAF, oxLDL and oxPL and compare 
these observations to those in AgP monocytes.  
 
In the DC and MO model (Chapter II), the low levels of IL-6 receptor upon the MO is the 
likely cause of the unresponsiveness of these cells to oxLDL. We have yet to fully-
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investigate the expression of IL-6 receptor upon NP and GAgP monocytes. It is possible 
that spontaneously differentiated GAgP monocytes that look like DC express higher 
levels of IL-6 receptor than do the macrophage-like NP monocytes. Given the similarity 
of the cells and their comparable responses this seems likely. However we cannot rule out 
the possibility that another underlying cause exists. For example AgP monocytes are 
known to produce elevated levels of IL-6 (Sun et al., 2009). IL-6 is elevated in 
atherosclerosis and periodontal disease (Ioannidou et al., 2006;Schieffer et al., 
2004;Shapira et al., 1994). Furthermore, apoE mice infected with the periodontitis-
associated pathogen P.gingivalis have accelerated atherosclerosis in comparison to 
uninfected apoE mice (Lalla et al., 2003). This is accompanied by increased plasma IL-6 
production in infected mice. It is possible that activated AgP monocytes have an 
increased potential to make IL-6 and that this contributes to their sensitivity to oxLDL 
and oxPAPC. 
 
While short-chain oxPL are proposed targets for PAFAH, long-chain oxPL are much less 
likely substrates for PAFAH given their sn-2 acyl chain length. However, recent studies 
suggest that these unlikely substrates are indeed targets of PAFAH although they are not 
as good substrates as the short-chain oxPL (Davis et al., 2008). If long-chain oxPL are 
indeed PAFAH substrates the high levels of PAFAH activity present in NP monocytes 
and macrophages is a potential additional explanation for their lack of response to long-
chain fractions of oxPAPC. 
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Overall our data reveal that like LAgP monocytes (Al Darmaki et al., 2003) GAgP 
monocytes have a propensity to differentiate into DC-like cells. These spontaneously 
differentiated monocytes express significantly lower basal levels of PAFAH than NP 
subjects’ monocytes. Additionally they respond like cytokine-differentiated DC to PAF, 
c-PAF, oxPAPC and oxLDL. This confirms the utility of cytokine-differentiated DC and 
macrophages as models for in vivo-differentiated DC and macrophages. The low PAFAH 
expression of GAgP monocytes as well as their propensity to differentiate into DC 
emphasizes the skewed lipid metabolism associated with the disease. In addition to low 
monocyte PAFAH expression, GAgP subjects have low LDL-associated PAFAH activity 
(Rufail et al., 2005). GAgP subjects also possess greater numbers of circulating LDL 
particles and these particles are smaller suggesting an increased prevalence of 
proatherogenic small-dense LDL (Rufail et al., 2005). Whether pro- or anti-inflammatory 
in the context of atherosclerosis, it is clear that PAFAH has a key role in development of 
this disease and further investigations into the regulation of this enzyme are warranted. 
The potential causes of the differential responses of AgP and NP monocytes to oxLDL 
and oxPAPC will be more thoroughly investigated in the future. 
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CHAPTER V: GENERAL DISCUSSION 
 
Despite its role in inflammation, the regulation of PAFAH is not well characterized. First 
identified as an enzyme involved in the regulation of the inflammatory response, PAFAH 
was considered to be protective. Since its discovery PAFAH has been linked with a 
variety of inflammatory diseases including periodontitis and type I diabetes (Elter et al., 
2003a;Gomes et al., 2008), retaining its protective status. More recently PAFAH has been 
connected with atherosclerosis. Controversy has surrounded the role of PAFAH in 
atherosclerosis however accumulating evidence suggests that PAFAH contributes to the 
progression of the disease (Ballantyne et al., 2005b;Wilensky et al., 2008). What is 
certain is that our limited understanding of the regulation of PAFAH prevents resolution 
of this issue. To elucidate the signals that regulate PAFAH will certainly increase our 
understanding of the role that this enzyme plays in atherosclerosis and inflammation in 
general. Furthermore, the study of PAFAH regulation will potentially lead to the 
generation of therapeutic targets for PAFAH itself or against regulators of this enzyme. 
This study addressed the potential for the regulation of PAFAH by its bioactive 
phospholipid targets.  
 
One of the major findings of this study is the differential responses that macrophages and 
DC make to PAF and oxPL. Other studies have demonstrated the differential regulation 
of PAFAH in macrophages and DC (Al Darmaki et al., 2003). Our research further 
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establishes the disparate responses of macrophages and DC to oxPL and PAF.  The 
relative abundance of PAFAH in macrophages is almost certainly a critical factor in the 
lack of response to PAF. This is illustrated by the sensitivity of macrophages to the non-
hydrolyzable PAF analog c-PAF. Our data also reveal that like LAgP monocytes, GAgP 
monocytes spontaneously differentiate into DC and respond like DC to PAF and oxLDL 
(Al Darmaki et al., 2003;Barbour et al., 2002c)(Figures 22-23). Previous reports showed 
that PAF induced the expression of PAFAH (Cao et al., 1998d) however we show that 
PAF suppresses PAFAH expression (Figure 24). This phenomenon would allow the 
persistence of PAF and therefore its inflammatory effects.  
 
PAF has long been associated with periodontitis. It is present in gingival crevicular fluid 
(Emingil et al., 2001) and correlates with disease severity (Garito et al., 1995). PAF 
accumulation has also been linked with necrotizing enterocolitis, Hepatitis C Virus, 
anaphylaxis and bronchial asthma (Caini et al., 2007;Hsueh et al., 2003;Tsukioka et al., 
1996;Vadas et al., 2008). In all of these diseases, elevated PAF is inversely associated 
with PAFAH. Our data reinforce the idea that PAF suppresses PAFAH during 
inflammation and that continued PAFAH suppression contributes to the inflammatory 
component of these diseases. Ultimately, in a chronic disease such as periodontitis where 
PAF is persistent, the prolonged suppression of PAFAH may result in chronic 
inflammation.  
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The recruitment of immature DC to the site of inflammation is mediated by PAF 
(Dichmann et al., 2000). As DC mature, expression of the PAF receptor is lost 
(Dichmann et al., 2000). During maturation, DC gain the ability to migrate to the lymph 
to activate T cells and promote the resolution of inflammation. PAF and PAF-like oxPL 
sequester DC at the site of inflammation (Angeli et al., 2004c). Migration is improved 
following treatment with the PAF receptor antagonist CV3988. The most dramatic 
restoration of DC migration was observed in PAF receptor knockout mice that showed 
two-fold greater emigration than their wild-type counterparts (Angeli et al., 2004c). 
These observations suggest that PAF prevents the migration of DC to the lymph. DC 
produce potent inflammatory cytokines and therefore the trapping of these cells at the site 
of inflammation would lead to the aggravation of the local immune response.  
 
PAF-like oxPL such as POVPC are generated during oxLDL generation (Marathe et al., 
2001). These short-chain oxPL may bind the PAF receptor to mimic PAF signaling such 
as inducing the adhesion of leukocytes to the endothelium (Lehr et al., 1993c;Pegorier et 
al., 2005). Our studies with PAF predict that these PAF-like oxPL would suppress 
PAFAH expression. Our preliminary data in THP1 monocytes indicate that POVPC may 
also suppress PAFAH expression (Figure 20). Surprisingly DC were unresponsive to 
POVPC suggesting a) that the sensitivity of DC is different to that of THP1 monocytes or 
b) that the mechanism for PAFAH suppression is not solely mediated by the PAF 
receptor. Importantly further experiments in THP1 monocytes treated with POVPC 
revealed that these cells are sensitive to POVPC. Moderate doses of POVPC, but not 
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PGPC led to cell death. There is evidence that POVPC induces apoptosis but at much 
greater concentrations than those used in this study. POVPC activates acid 
sphingomyelinase to promote apoptosis in smooth muscle cells (Fruhwirth et al., 
2006;Loidl et al., 2003). Increased activity of the enzyme sphingomyelinase converts 
sphingomyelin to ceramide, a potent mediator of apoptosis. Apoptosis of smooth muscle 
cells and monocytes may contribute to the instability of the plaque and therefore plaque 
rupture and breakdown. Hydrolysis of POVPC by PAFAH may therefore be protective in 
this instance, although high concentrations of LPC may themselves be apoptotic. The 
PAFAH inhibitor Darapladib prevents expansion of the necrotic core (Mohler, III et al., 
2008). This suggests that a decrease in the products of PAFAH activity protect the 
atheroma. As high concentrations of LPC induce cell death and likely contribute to the 
necrotic core this suggests that the outcome of PAFAH activity is the development and 
instability of the atheroma. The sensitivity to POVPC and cell death resulting from 
treatment with this oxPL should be further evaluated. We are intrigued by the sensitivity 
of monocytes to POVPC and further studies will investigate whether lower doses regulate 
PAFAH expression.  
 
Long-chain oxPL are unlikely targets for PAFAH given their sn-2 acyl chain length. 
However, a recent study demonstrated that a class of long-chain oxPL that lie within the 
range of PEIPC are abundant in oxLDL are PAFAH substrates (Davis et al., 2008). It is 
important to note that this study also admitted that long-chain oxPL are not as efficient 
substrates as short-chain oxPL (Davis et al., 2008). PEIPC is the best characterized and 
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perhaps most bioactive of the long-chain fraction of oxPAPC. It is well established that 
oxidation of the sn-2 acyl chain partially offsets the loss of preference for longer chain 
length (Stremler et al., 1989b;Stremler et al., 1991). Given this information it is possible 
that MO and differentiated NP monocytes hydrolyze long-chain oxPAPC. PAFAH is 
significantly elevated in these cells and it is possible that the high activity, combined with 
a deficiency of IL-6R is sufficient to eradicate any of the signaling effects that we 
observe in DC, monocytes and differentiated AgP monocytes. An important extension of 
our results will be to utilize pharmacological inhibitors of PAFAH to determine the 
relative impact of the enzyme upon the macrophages. If PAFAH is catabolyzing the long-
chain oxPL over the incubation period we will expect to see an induction, although 
perhaps modest in macrophage PAFAH expression. Additionally, the use of PAFAH 
inhibitors such as Pefabloc or Darapladib in DC would perhaps suppress PAFAH activity 
allowing an even more prolific response. Low DC PAFAH activity may not be such an 
important factor in oxPAPC-induced PAFAH expression. In support of this argument is 
the monocyte, with extremely low levels of PAFAH, the monocyte responds no better to 
DC to oxPAPC.  
 
Berliner’s group was the first to show that pure PEIPC binds the prostaglandin receptor 
subtypes DP1 and EP2 (Li et al., 2006f). These studies were conducted in endothelial 
cells that express EP2 alone (Li et al., 2006g). To our knowledge, our study is the first to 
investigate signaling of oxPAPC through both DP1 and EP2. We show that PEIPC-
containing long-chain fractions of oxPAPC induce PAFAH expression in DC and 
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monocytes (Figure 10). The potential for oxPL binding a G-protein coupled receptor was 
first demonstrated by the activation of endothelial cell cAMP by minimally modified 
LDL (Parhami et al., 1993). More recently PEIPC was shown to bind DP1 and EP2, both 
of which are coupled to Gsα subunits (Liu et al., 2002a). Activation of both receptors 
leads to the production of IL-6 (Chapter II). Other investigators have shown that oxPAPC 
stimulates IL-6 production and that PEIPC can activate downstream components of the 
IL-6 signaling pathway such as Stat3 (Furnkranz et al., 2005d;Imai et al., 2008;Yeh et al., 
2004). IL-6 is required for optimal responses to oxPAPC (Furnkranz et al., 2005a;Van 
Lenten et al., 2001a). Our data reveal that the long-chain fraction of oxPAPC induces IL-
6 expression and that this is required for optimal PAFAH expression (Figure 13). 
Preliminary data reveals that Stat3 activation through tyrosine and serine phosphorylation 
occurs following treatment with oxPAPC (Figure 13). The 5’ flanking regions of both IL-
6 and PAFAH contain canonical GAS elements that potentially bind activated Stat3. 
Mice that have selective deletion of endothelial Stat3 develop smaller atherosclerotic 
lesions than wild type mice (Gharavi et al., 2006). Pravastatin treated ApoE null mice 
have significantly reduced atherosclerotic lesions, reduced levels of IL-6 and 
phosphorylated Stat3 (Zhou et al., 2008). Expression of the adhesion protein intercellular 
adhesion molecule-1 (ICAM-1) is induced following the formation of a complex between 
Stat3 and Sp1 that binds a GAS element (Yang et al., 2005). The PAFAH 5’ flanking 
region contains a canonical GAS sequence (TTCAGAGAA) that is located within 
approximately 250 nucleotides of the GC-box (Cao et al., 1998e)(Figure 27). We 
hypothesize that oxPAPC-induced activation of Stat3 leads to its association with Sp1 
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thereby inducing PAFAH expression. This is a novel system for the regulation of 
PAFAH. Further studies are required to investigate the role of Stat3 in oxPAPC-induced 
PAFAH expression. Our studies will use pharmacological inhibitors of Stat3 as well as 
the generation of modified PAFAH promoter constructs that will test whether Stat3 is a 
requirement for the upregulation of PAFAH expression. Furthermore we will investigate 
the potential for oxPAPC-activated Stat3 forming a complex with Sp1 to induce PAFAH 
expression.  
 
This study revealed that macrophages generated from primary monocytes in vitro express 
very low levels of the IL-6 receptor (Figure 13). This, perhaps combined with their high 
PAFAH expression renders them largely unresponsive to oxPAPC. Given that 
macrophages are classically associated with atherosclerosis, we are particularly intrigued 
that their PAFAH regulation is unaffected by oxidized phospholipids. These bioactive 
lipids are important to the development of atherosclerosis and it is therefore interesting 
that monocytes and DC alone respond. Macrophages express both DP1 and EP2 (Figure 
11) and we predict that they are able to bind PEIPC in long-chain fractions of oxPAPC. 
Macrophages may hydrolyze these oxPL too rapidly to allow them to bind these receptors 
however given that they are less efficient substrates we predict that a fraction of these 
oxPL persist. oxPL binding would lead to IL-6 production but the low expression of the 
IL-6 receptor predicts that IL-6 does not signal in an autocrine fashion upon the 
macrophage. We predict that macrophage-generated IL-6 in the atheroma would instead 
bind IL-6 receptors upon the DC and reinforce the upregulation of PAFAH. This would 
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lead to a massive induction of PAFAH in the atheroma and potentially contributes to the 
elevated PAFAH levels observed in atherosclerosis. This notion should be tested in future 
experiments for example by stimulating macrophages with oxPAPC and incubating DC 
with the conditioned media from these studies.  
 
IL-6 is not solely generated by oxPAPC. While our observations with oxPAPC are 
important to atherosclerosis, we must recognize that other factors are present in the 
atheroma that could potentially elevate IL-6 levels to induce PAFAH. One factor in 
particular is sphingosine 1-phosphate (S1P). The bioactive lipid S1P induces IL-6 release 
from macrophages (Price et al., 2009). S1P is implicated in atherosclerosis although it is 
unknown whether its role is pro- or anti-atherogenic. S1P stimulates proliferation and 
migration of vascular smooth muscle cells, both are pro-atherogenic actions (Levade et 
al., 2001). Additionally S1P exerts anti-apoptotic effects upon T cells and leukocytes, this 
would allow persistence of these cells in the atheroma and allow them to continue to 
produce inflammatory cytokines (Cuvillier et al., 1998). Conversely, HDL-associated 
S1P is reported to be protective in cardiovascular disease (Sattler and Levkau, 2009).  
 
OxPAPC has been demonstrated by other investigators to signal through several 
receptors in addition to DP1/EP2 including the TLR/CD14 receptor complex (Erridge et 
al., 2008;Miller et al., 2003;Miller et al., 2005;Walton et al., 2003a). LPS the classic 
ligand for TLR4 induces PAFAH expression by increasing the activity of Sp1 (Wu et al., 
2003). The transcription factors Sp1 and Sp3 are required for basal PAFAH activity (Wu 
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et al., 2003). oxPAPC suppresses LPS signaling in endothelial cells (Bochkov et al., 
2002). Our own preliminary experiments indicate a similar phenomenon in THP1 
monocytes (Figure 26). Presently there is no definitive cause for these observations. 
There is speculation that oxPAPC can interfere with the construction of the LPS/TLR4 
receptor complex either by binding directly to a component of the signaling unit or by 
disruption of the complex by membrane alterations (Bochkov et al., 2002;Erridge et al., 
2008). We are intrigued by our similar observations in THP1 monocytes especially 
considering our findings with oxPAPC and IL-6 and the regulation of PAFAH. Other 
reports have shown that IL-6 also suppresses LPS signaling in DC (Hegde et al., 2004). 
This research also demonstrated suppression of the chemotactic response of 
phenotypically mature DC towards CCR7, an action that would lead to the trapping of 
DC in the atheroma. Importantly, IL-6 also suppressed LPS-stimulated activation of NF-
kB. This is particularly interesting given the lack of NF-kB signaling downstream of 
oxPL. The authors concluded that DC incubated with IL-6 were phenotypically mature 
but functionally impaired DC (Hegde et al., 2004). This notion that is intriguing when 
one considers that DC become trapped at sites of dyslipidemia mimicking atherosclerosis 
(Angeli et al., 2004c). All together these data suggest that IL-6 participates in the 
oxPAPC-mediated suppression of LPS signaling.   
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Figure 26: oxPAPC Suppresses LPS Signaling in THP-1 Monocytes. THP1 
monocytes were treated with 100ng/ml LPS, 10µg/ml oxPAPC or both for 16 hours then 
PAFAH expression was quantified by qPCR. The data represent a single experiment 
conducted in triplicate. Data are expressed as mean ± standard deviation relative to 
control. 
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Figure 27: Depiction of the PAFAH 5’ flanking region. +1 refers to transcription start 
site. The GC-box has been confirmed.  The sequence of the putative GAS element is 
TTCAGAGAA (-340 - -332).  The proposed negative regulatory regions are inferred 
from analyses of transcriptional activity in truncated constructs by other investigators. 
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OxPL have also been demonstrated to induce IL-8 through the activation of Stat3 
(Gharavi et al., 2006). Preliminary work conducted in our laboratory indicates that IL-8 
may also regulate PAFAH expression (Figure 28). Intriguingly, IL-8 treatment of DC and 
macrophages follows a similar pattern to IL-6 treatment where macrophages are largely 
unresponsive (Figure 28). Further studies are warranted to investigate this intriguing 
observation and to determine whether oxPAPC induces IL-8 in the monocytic cell model. 
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Figure 28: IL-8 Induces PAFAH Expression. Cytokine-differentiated macrophages and 
dendritic cells were treated with IL-8 at the indicated concentrations for 16 hours. Cell 
free supernatants were subjected to PAFAH activity assays.  
 
 
 
 
(Data generated by Muralikrishna Mukkamala)
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Our data reveal that mildly oxidized preparations of LDL alone can significantly induce 
PAFAH expression (Figure 14). Our method for the oxidation of LDL was originally 
used by Anthonsen et al to study the regulation of sPLA2 by oxLDL (Anthonsen et al., 
2000c). They too found that mildly oxidized LDL was the strongest inducer of their 
phospholipase A2 and that further oxidation led to the loss of any significant changes in 
sPLA2 expression. While mild oxidation of LDL likely leads to the production of long-
chain oxPL, heavy oxidation continues the modification and fragmentation of the sn-2 
acyl chain likely leading to the generation of short-chain, PAF-like oxPL. Other studies 
have revealed that minimally oxLDL can offset the effects of extensively oxLDL 
(Boullier et al., 2006). Further studies with mass spectrometry are warranted to 
investigate the relative component oxPL of the species of oxLDL. It is possible that 
PAFAH expression is not induced because the long-chain oxPL become fragmented but 
equally as possible is that the emergence of PAF-like oxPL leads to the suppression of 
the long-chain oxPL response. These observations are important when one considers the 
outcome in the atheroma. Early in atherosclerosis when long-chain oxPL are abundant, 
one would predict that PAFAH expression would be robustly upregulated. As more 
extensive oxidation occurs, the relative level of PAFAH may decline. In agreement with 
this notion, PAFAH levels are elevated in early atherosclerosis but are later almost 
undetectable.  
 
This study reveals DC to be important mediators of the response to oxPAPC. DC are 
sensitive to long-chain fractions of oxPAPC unlike the unresponsive macrophages 
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(Figure 10). Macrophages have long been associated with atherosclerosis however the 
role of DC in atherosclerosis is an emerging field. Bobryshev identified that DC are not 
only present in the atheroma but are localized to rupture-prone shoulder regions of the 
plaque (Bobryshev, 2000b). DC are also thought to be involved in maturation of the 
plaque and perhaps in the instability of advanced lesions (Bobryshev, 2000c). Our data 
reveal that PAFAH activity is significantly upregulated in DC. Elevated DC PAFAH may 
lead to the catabolism of oxPL and thus the generation of LPC. LPC induces apoptosis 
and interferes with membrane integrity and could be the source of the instability at 
shoulder regions of the plaque. Angeli et al showed that DC may become trapped in the 
atheroma (Angeli et al., 2004c). This, together with our data strongly suggests that 
oxPAPC-stimulated DC are the cause of plaque instability.  
 
PAFAH has been the source of much controversy regarding its role in atherosclerosis. 
The elevated levels of the enzyme detected in atherosclerosis are undeniable (Packard et 
al., 2000b;Tselepis and Chapman, 2002a;Wilensky et al., 2008). Our study shows that 
long-chain oxPL are, at least in part responsible for the induction of PAFAH observed. 
PAFAH degrades pro-inflammatory oxPL. These oxPL are known to stimulate 
monocyte-migration to the atheroma, induce differentiation and smooth muscle cell 
proliferation and migration (Chatterjee et al., 2004;Cherepanova et al., 2009;Frostegard et 
al., 1997c). The catabolism of these oxPL would therefore suppress these pro-atherogenic 
activities and protect the artery from further damage. The ultimate outcome of PAFAH 
however may also be damaging as the products of the reaction, LPC and oxidized free 
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fatty acids are also potent pro-inflammatory mediators. Treatment of THP1 monocytes 
with POVPC leads to cell death. At this stage we do not know whether this is a direct 
consequence or whether POVPC is catabolyzed and the products of the reaction are the 
cell death stimulus. There are many examples of the protective effects of PAFAH in 
animal models. For example increased PAFAH reduces atherosclerosis and neointimal 
formation (Arakawa et al., 2005b;Quarck et al., 2001b;Turunen et al., 2005b). PAFAH is 
also able to restore the migration of DC to the lymph in apoE null mice (Angeli et al., 
2004c). These examples are likely a consequence of the catabolism of oxPL. While LDL-
associated PAFAH is often damaging, HDL-associated PAFAH may be protective. For 
example it is HDL-associated PAFAH that restores DC migration out of the atheroma. 
Conversely PAFAH is also associated with increased incidence of cardiovascular disease 
(Blankenberg et al., 2003a;Stafforini et al., 1987a;Stafforini et al., 1997b) and directly 
correlates with lesion severity severity (Hakkinen et al., 1999). These observations are 
likely a direct consequence of the products of the PAFAH reaction. A PAFAH inhibitor, 
Darapladib is currently in Phase III clinical trials. Darapladib transiently decrease 
circulating C-reactive protein (CRP) and interleukin-6 (IL-6) (Mohler, III et al., 2008) 
Additionally, there is a significant reduction in necrotic core progression suggesting that 
PAFAH does indeed play a role in atherosclerosis development (Wilensky et al., 2008). 
We are intrigued by the transient nature of the CRP and IL-6 suppression. These studies 
suggest while short-term inhibition of PAFAH lowers inflammation, long-term 
inflammation is restored. This suggests that over time, the suppression of PAFAH may 
not be as protective. While suppression of PAFAH in the atheroma appears to have a 
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protective outcome, the global suppression of PAFAH may impact the resolution of 
inflammation by allowing persistently elevated levels of PAF. Furthermore, the inhibition 
of PAFAH in the atheroma allows the accumulation of oxPL that signal the influx of 
monocytes as well as a variety of pro-inflammatory events. We predict that while 
PAFAH is a key player in the progression of the atheroma, it retains some anti-
atherogenic and anti-inflammatory characteristics. We predict that the long-term 
inhibition of this enzyme may impact inflammation in general.  
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